B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Independent Auditor's Report

To the Members of Manipal Hospitals Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Manipal Hospitals Private Limited (the "Company") which comprise the standalone balance sheet as at 31 March 2026, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, and its profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter - Impairment of Investments in Sahyadri Hospitals Private Limited	
See Note 2.2 (a) and Note 5.1 to standalone financial statements	
The key audit matter	**How the matter was addressed in our audit**
On 3 October 2025, the Company acquired a controlling stake in Sahyadri Hospitals Private Limited ("SHPL"). The investment in SHPL is significant amounting to INR 5,793.09 crores as at 31 March 2026. The Company assesses, if there is an indication, based on either internal or external sources of information, that the	In view of the significance of the matter, we performed the following audit procedures in this area, amongst others to obtain sufficient appropriate audit evidence: • Assessing the appropriateness of accounting policy for impairment of investment in

investment in SHPL may be impaired. Accordingly, the Company has performed a detailed impairment assessment, involving an expert and determining the recoverable value of the investment. Such assessment involves use of several key assumptions and any changes to these assumptions could result in changes in the recoverable values. In view of the significance of the carrying amount of investment and significant judgments required to compute the recoverable value, this is identified as a key audit matter.	subsidiaries as per the relevant accounting standards. • Evaluating the design and implementation of key internal financial controls relating to impairment process and testing the operating effectiveness of these controls. • Evaluating the assessment of impairment indicators with respect to investments in SHPL, considering internal or external sources of information, as performed by the Company. • Assessing the adequacy of the level of impairment by: evaluating with the help of valuation specialists, where required, appropriateness of the valuation methodology and key assumptions, namely sales growth, operating costs, weighted average cost of capital and terminal growth rate; performing sensitivity analysis of the key assumptions. • Assessing the adequacy of disclosures in the standalone financial statements in accordance with the relevant accounting standards.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management's and Board of Directors' Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.

- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2 A. As required by Section 143(3) of the Act, we report that:

a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matters stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

c. The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.

d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

e. On the basis of the written representations received from the directors on 31 March 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164(2) of the Act.

f. the modifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2A(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

a. The Company has disclosed the impact of pending litigations as at 31 March 2026 on its financial position in its standalone financial statements - Refer Note 30 to the standalone financial statements.

b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

d (i) The management has represented that, to the best of their knowledge and belief, as disclosed in the Note 42 (vi) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The management has represented that, to the best of their knowledge and belief, as disclosed in the Note 42 (vii) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e. The Company has neither declared nor paid any dividend during the year.

f. Based on our examination which included test checks, except for the instance mentioned below, the Company has used accounting softwares for maintaining its books of account which have a feature of audit trail (edit log), and the same has operated throughout the year for all relevant transactions recorded in the respective accounting softwares:

- The feature of audit trail (edit log) facility was not enabled at the data base level to log any direct data changes in respective accounting softwares.

Further, where audit trail (edit log) feature was enabled and operated during the year for the respective accounting software, we did not come across any instance of the audit trail (edit log) being tampered with. Additionally, where the audit trail (edit log) feature was enabled in the previous years, the audit trail (edit log) has been preserved by the Company as per the statutory requirements for record retention.

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the Company has not paid any remuneration to its directors during the year. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

G Prakash

Partner

Membership No.: 099696

ICAI UDIN:26099696CDJAYU2340

Place: Bengaluru

Date: 22 May 2026

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment and Right of use assets.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of use assets) or intangible assets or both during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The inventory, has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets, however as informed by management, no quarterly returns or statements are required to be filed by the Company with such banks.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has made investments in and granted loans to companies and other parties. The Company has provided security to companies. The Company has not made any investments in, granted any loans to or provided security to firms or limited liability partnerships. The Company has not provided security to any other parties. The Company has not stood guarantee or granted any advances in the nature of loans, secured or unsecured, to any companies, firms, limited liability partnerships, or other parties during the year. Details of the loans granted and securities provided are stated in subclause (a) as below:

(a) Based on the audit procedures carried on by us and as per the information and explanations given to us the Company has granted loans and provided security as below:

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

Particulars	Security (in Rs. crore)	Loans (in Rs. crore)
Aggregate amount during the year		
Holding Company*	#	-
Fellow Subsidaries*	#	-
Subsidiaries*	#	371.70
Others^	5,310	0.17
Balance outstanding as at balance sheet date		
Holding Company*	#	-
Fellow Subsidiaries*	#	-
Subsidiaries*	#	-
Others^	5,310	0.09

**As per the Companies Act, 2013*

#During the year, the Company along with its Holding company, its Subsidiary and its Fellow Subsidiaries has provided security to various lenders with respect to term loans amounting to Rs. 4,930.63 crore taken by the Company, its Holding Company, its Subsidiary and its Fellow Subsidiaries. Also, refer note 30 (iii) to the financial statements.

^ The Company has created a pledge over the equity shares of Sahyadri Hospitals Private Limited in favour of the debenture trustee.

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made, security given during the year and the terms and conditions of the grant of loans provided during the year are not prejudicial to the interest of the Company. Further, the Company has not stood guarantee or given any advance in the nature of loan to any party during the year.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, in our opinion the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular. The Company does not charge interest for loans granted to its employees. Further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given. Further, the Company has not given any advances in the nature of loans to any party during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to same parties.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment.

(iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and loans and security given by the

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

Company, in our opinion the provisions of Section 185 of the Companies Act, 2013 ("the Act") have been complied with. Further, there are no investments, loans, guarantees and security in respect of which provisions of section 186 of the Act are applicable.

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of healthcare services (including pharmacy sales) provided by it and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.

(vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited with the appropriate authorities, though there have been delays in a few cases of provident fund, professional tax and unclaimed statutory bonus.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2026 for a period of more than six months from the date they became payable, except as mentioned below:

Name of the statute	Nature of the dues	Period to which the amount relates	Amount (Rs. in crore)	Due date	Date of payment
The Payment of Bonus Act 1965 and labour welfare fund regulations of respective states	Unpaid Accumulations related to Bonus	2015 - 16	0.01	30 November 2018	Yet to be paid
		2016 - 17	0.04	30 November 2019	Yet to be paid
		2017 - 18	0.02	30 November 2020	Yet to be paid
		2018 - 19	0.02	30 November 2021	Yet to be paid
		2019 - 20	0.02	30 November 2022	Yet to be paid
		2022-23	0.27	30 November 2025	Refer note below #

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

Name of the statute	Nature of the dues	Period to which the amount relates	Amount (Rs. in crore)	Due date	Date of payment
The Employee Provident Fund and Miscellaneous Provisions Act, 1952	Provident Fund	March to October 2019	0.17	Various	Yet to be paid

The Company has paid 0.16 crores on 21 May 2026.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company does not have disputed dues relating to Provident Fund, Employees State Insurance, Duty of Customs or Cess. The disputed statutory dues relating to Goods and Service Tax, Service Tax and Income Tax which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in crore) #	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
Goods and Service Tax Act, 2017	Goods and Service Tax	14.36	2017 - 2025	High Court of Karnataka	
Goods and Service Tax Act, 2017	Goods and Service Tax	11.59	2017 - 2022	High Court of Karnataka	Out of the total disputed amount of Rs. 25.38 crore, Rs. 13.79 crore towards the demand of GST (without interest) paid under protest.
Goods and Service Tax Act, 2017	Goods and Service Tax	6.71	2021-2023	High Court of Karnataka	
Finance Act, 1994	Service Tax	6.55	2014 - 2017	CESTAT	Out of the total disputed amount of Rs. 10.10 crore, Rs. 3.55 crore paid under

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

Name of the statute	Nature of the dues	Amount (Rs. in crore) #	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
					protest.
Finance Act, 1994	Service Tax	0.99	2014 - 2017	Commissioner of Service Tax (Appeals)	Out of the total disputed amount of Rs. 1.30 crore, Rs. 0.31 crore paid under protest
Income Tax Act, 1961	Income Tax	1.69	2018-19	Commissioner of Income Tax (Appeals) ^	
Income Tax Act, 1961	Income Tax	0.40	2019-20	Commissioner of Income Tax (Appeals) ^	
Income Tax Act, 1961	Income Tax	0.67	2022-23	Commissioner of Income Tax (Appeals) ^	
Income Tax Act, 1961	Income Tax	0.84	2023-24	Commissioner of Income Tax (Appeals) ^	

Including interest and penalty where applicable.

^ The Company has subsequently received a favourable order from Commissioner of Income Tax (Appeals). The appeal timelines for the income-tax department have not lapsed as of date of our report.

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

(e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Act.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has raised loans during the year on the pledge of securities held in its subsidiary as per details below:

Nature of loan taken	Name of lender	Amount of loan (Rs. in crores)	Name of the subsidiary	Relationship	Details of security pledged	Remarks
Non-convertible debenture	Multiple^	5,310	Sahyadri Hospitals Private Limited	Subsidiary	Equity shares held by the Company	

^ The Company has created a pledge in favour of the debenture trustee as required under the terms of the debenture trust deed.

Further the repayment of such loans raised has not fallen due during the year.

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the year.

(b) A report under sub-section (12) of Section 143 of the Act has been filed by us in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government subsequent to the reporting date for a matter identified during the year. However, this has not been considered for our reporting in clause (a) above on the basis of materiality.

(c) We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.

(xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) According to the information and explanations provided to us, the Group (as defined in the regulations made by the Reserve Bank of India) does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) We draw attention to Note 2.1(b) to the standalone financial statements which explains that the Company's current liabilities exceed its current assets as at 31 March 2026 by Rs. 304.41 crores.

The Company has evaluated its ability to continue as a going concern based on the assessment of its cash position and future cash flow forecast. The Company has also received letter of support from its holding company.

On the basis of the above and according to the information and explanations given to us, on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

Also refer to the Other Information paragraph of our main audit report which explains that the other information comprising the information included in annual report is expected to be made available to us after the date of this auditor's report.

(xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly,

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

G Prakash
Partner
Membership No.: 099696
ICAI UDIN:26099696CDJAYU2340

Place: Bengaluru
Date: 22 May 2026

Annexure B to the Independent Auditor's Report on the standalone financial statements of Manipal Hospitals Private Limited for the year ended 31 March 2026

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Manipal Hospitals Private Limited ("the Company") as of 31 March 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2026, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Annexure B to the Independent Auditor's Report on the standalone financial statements of Manipal Hospitals Private Limited for the year ended 31 March 2026 *(Continued)*

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Prakash

G Prakash
Partner
Membership No.: 099696
ICAI UDIN:26099696CDJAYU2340

Place: Bengaluru
Date: 22 May 2026

Manipal Hospitals Private Limited
CIN:U85110KA2003PTC033055
Standalone Balance Sheet as at

	Note	March 31, 2026	March 31, 2025
			(₹ in crores)
ASSETS			
Non-current assets			
Property, plant and equipment	3.1	765.82	752.97
Capital work-in-progress	3.2	62.35	13.33
Right-of-use assets	4.1	385.31	393.13
Intangible assets	4.2	23.02	27.80
Financial assets			
Investments	5.1	6,645.96	730.40
Loans	5.2	-	12.41
Other financial assets	5.3	27.07	25.60
Deferred tax assets (net)	14	16.50	16.56
Income tax assets (net)	6	73.92	11.25
Other non-current assets	7	18.82	20.12
		8,018.77	**2,003.57**
Current assets			
Inventories	8	36.35	31.37
Financial assets			
Investments	9.1	653.47	399.07
Trade receivables	9.2	160.74	109.47
Cash and cash equivalents	9.3	54.65	65.21
Loans	9.4	0.13	0.26
Other financial assets	9.5	13.37	12.52
Other current assets	10	10.20	10.55
		928.91	**628.45**
Assets held for sale	3.3	6.50	6.50
Total assets		**8,954.18**	**2,638.52**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	1,025.30	1,025.30
Other equity	12	431.86	225.33
Total equity		**1,457.16**	**1,250.63**
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	13.1	5,669.78	407.99
Lease liabilities	13.2	588.31	574.16
Other financial liabilities	13.3	5.61	-
		6,263.70	**982.15**
Current liabilities			
Financial liabilities			
Borrowings	15.1	332.52	61.47
Lease liabilities	13.2	14.06	11.69
Trade payables	15.2		
- total outstanding dues of micro enterprises and small enterprises		8.86	6.11
- total outstanding dues of creditors other than micro enterprises and small enterprises		283.65	268.89
Other financial liabilities	16	565.36	22.56
Other current liabilities	18	17.54	20.17
Provisions	17	11.33	13.07
Current tax liabilities (net)	19	-	1.78
		1,233.32	**405.74**
Total equity and liabilities		**8,954.18**	**2,638.52**
Material accounting policies	2.2		

The accompanying notes are an integral part of standalone financial statements

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm Registration number : 101248W/W - 100022

G Prakash
Partner
Membership number: 099696

Place : Bengaluru
Date : May 22, 2026

For and on behalf of the Board of Directors of
Manipal Hospitals Private Limited

Dr. H. Sudarshan Ballal
Chairman

Deepak Venugopalan
Chief Executive Officer

Pratik Gupta
Chief Financial Officer

Khadija G Vahora
Company Secretary
Membership number A37266

Place : Bengaluru
Date : May 22, 2026

Manipal Hospitals Private Limited
CIN:U85110KA2003PTC033055
Standalone Statement of Profit and Loss for the year ended

	Note	March 31, 2026	(₹ in crores) March 31, 2025
Income			
Revenue from operations	20	2,474.30	2,153.75
Other income	21	63.97	25.36
Total income		**2,538.27**	**2,179.11**
Expenses			
Purchase of medical consumables and pharmacy items		430.14	367.23
Changes in inventories of medical consumables and pharmacy items	22	(4.98)	(4.10)
Employee benefits expense	23	269.69	240.97
Finance costs	24	422.45	116.89
Depreciation and amortisation expense	25	121.40	125.63
Other expenses	26	1,007.51	886.95
Total expenses		**2,246.21**	**1,733.57**
Profit before exceptional items and tax		**292.06**	**445.54**
Exceptional items	27	(16.76)	-
Profit before tax		**275.30**	**445.54**
Tax expense			
Current tax	14	69.49	116.11
Deferred tax	14	(0.13)	(1.79)
Total tax expense		**69.36**	**114.32**
Profit for the year		**205.94**	**331.22**
Other comprehensive income (OCI)			
Items that will not be reclassified subsequently to profit and loss:			
Re-measurement of defined benefit plans		0.79	(1.35)
Income tax effect on above		(0.20)	0.33
Other comprehensive income/(loss) for the year (net of tax)		**0.59**	**(1.02)**
Total comprehensive income for the year		**206.53**	**330.20**
Earnings per equity share			
[nominal value of share ₹ 10]	28		
Basic (₹)		2.01	3.23
Diluted (₹)		2.01	3.23
Material accounting policies	2.2		

The accompanying notes are an integral part of standalone financial statements

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm Registration number : 101248W/W - 100022

G Prakash
Partner
Membership number: 099696

Place : Bengaluru
Date : May 22, 2026

For and on behalf of the Board of Directors of
Manipal Hospitals Private Limited

Dr. H. Sudarshan Ballal
Chairman

Deepak Venugopalan
Chief Executive Officer

Pratik Gupta
Chief Financial Officer

Khadija G Vahora
Company Secretary
Membership number: A37266

Place : Bengaluru
Date : May 22, 2026

Manipal Hospitals Private Limited
CIN:U85110KA2003PTC033055
Standalone Statement of Changes in Equity for the year ended March 31, 2026

(a) Equity share capital*

Equity shares of ₹ 10 each, issued, subscribed and fully paid-up	Nos.	(₹ in crores)
Balance as at April 01, 2025	1,02,52,97,268	1,025.30
Change in equity share capital during the year	-	-
Balance as at March 31, 2026	**1,02,52,97,268**	**1,025.30**
Balance as at April 01, 2024	1,02,52,97,268	1,025.30
Change in equity share capital during the year	-	-
Balance as at March 31, 2025	**1,02,52,97,268**	**1,025.30**

* Also, refer note 11

(b) Other equity**

(₹ in crores)

	Reserves and Surplus				Other comprehensive Income	
	Securities premium	Debenture redemption reserve	Retained earnings	Amalgamation adjustment deficit account	Re-measurement of defined benefit plan	Total other equity
Balance as at April 01, 2025	**246.89**	-	**38.67**	**(59.11)**	**(1.12)**	**225.33**
Profit for the year	-	-	205.94	-	-	205.94
Other comprehensive income for the year (net of tax)	-	-	-	-	0.59	0.59
Total comprehensive income	**246.89**	-	**244.61**	**(59.11)**	**(0.53)**	**431.86**
Transferred on account of surplus in retained earnings	-	-	(59.11)	59.11	-	-
Transferred to Debenture redemption reserve[4]		185.50	(185.50)	-	-	-
Balance as at March 31, 2026	**246.89**	**185.50**	-	-	**(0.53)**	**431.86**

	Reserves and Surplus				Other comprehensive Income	
	Securities premium	Debenture redemption reserve	Retained earnings	Amalgamation adjustment deficit account	Re-measurement of defined benefit plan	Total other equity
Balance as at April 01, 2024	**246.89**	-	**(292.55)**	**(59.11)**	**(0.10)**	**(104.87)**
Profit for the year	-	-	331.22	-	-	331.22
Other comprehensive loss for the year (net of tax)	-	-	-	-	(1.02)	(1.02)
Total comprehensive income	**246.89**		**38.67**	**(59.11)**	**(1.12)**	**225.33**
Balance as at March 31, 2025	**246.89**	-	**38.67**	**(59.11)**	**(1.12)**	**225.33**

** Also, refer note 12
Note : There are no changes in the accounting policies or prior period events during the current year or previous year.

Below is the nature and purpose of each reserve:

1. **Securities premium** - Securities premium is used to record the premium received on issue of shares.
2. **Re-measurement of defined benefit plan** - Represents remeasurement gains / (losses) on defined benefit plans (net of tax).
3. **Retained earnings** - Retained earnings comprises of prior and current period's undistributed earnings after tax
4. **Debenture redemption reserve** - The Companies Act requires that where a Company issues debentures, it shall create a debenture redemption reserve out of profits of the Company available for payment of dividend. The Company has issued Non-convertible debentures ("NCD") during the year. As per the provisions of the Companies Act, 2013, the Company has created debenture redemption reserve to the extent of its retained earnings available. The amounts credited to the debenture redemption reserve may not be utilised by the Company except to redeem debentures.
5. **Amalgamation adjustment deficit account** - It represents excess of consideration over carrying value of net assets (including reserves) in case of common control business combination. When there is a surplus in the Statement of profit and loss, this debit can be adjusted against that surplus.

Material accounting policies (refer note 2.2)

The accompanying notes are an integral part of standalone financial statements

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm Registration number : 101248W/W - 100022

G Prakash
Partner
Membership number: 099696

Place : Bengaluru
Date : May 22, 2026

For and on behalf of the Board of Directors of
Manipal Hospitals Private Limited

Dr. H. Sudarshan Ballal
Chairman

Deepak Venugopalan
Chief Executive Officer

Pratik Gupta
Chief Financial Officer

Khadija G Vahora
Company Secretary
Membership number: A37266

Place : Bengaluru
Date : May 22, 2026

Manipal Hospitals Private Limited
CIN:U85110KA2003PTC033055
Statement of Cash flow for the year ended

(₹ in crores)

	March 31, 2026	March 31, 2025
A. Cash flows from operating activities		
Profit before tax	275.30	445.54
Adjustments for:		
Depreciation and amortisation expense	121.40	125.63
Bad debts/advances written off	13.25	16.07
Loss allowance on trade receivables (net)	9.05	4.76
Loss allowance on other receivables (net)	0.11	0.10
Profit on sale of investments in mutual funds (net)	(12.32)	(3.48)
Profit on sale of property, plant and equipment (net)	(0.46)	(0.78)
Fair value gain on financial instruments at FVTPL	(26.49)	(13.57)
Interest income	(24.70)	(6.10)
Finance costs	416.00	107.03
Operating profit before working capital changes	**771.14**	**675.20**
Movements in working capital :		
Change in inventories	(4.98)	(4.10)
Change in trade receivables	(73.57)	(45.99)
Change in loans	0.13	(0.06)
Change in other financial assets	(0.54)	(0.29)
Change in other assets	(0.01)	0.02
Change in trade payables	(27.01)	(85.77)
Change in other financial liabilities	0.04	0.02
Change in other liabilities	(2.64)	3.17
Change in provisions	0.48	(7.29)
Cash generated from operations	**663.04**	**534.91**
Income tax paid (net)	(133.97)	(67.42)
Net cash generated from operating activities	**529.07**	**467.49**
B. Cash flow from investing activities		
Acquisition of property, plant and equipment and intangible assets	(147.32)	(98.26)
Proceeds from sale of property, plant and equipment	1.31	1.73
Acquisition of subsidiary	(5,268.44)	-
Investment in other entities	(2.42)	(0.02)
Loans given to related parties	(371.70)	(314.90)
Loans repaid by related parties	384.11	335.95
Investment made in bank deposits (having original maturity of more than three months)	(1.29)	(1.44)
Purchase of investments in mutual funds	(1,566.43)	(1,317.58)
Proceeds from the sale of investments in mutual funds	1,227.56	993.26
Interest received	23.76	6.09
Net cash used in investing activities	**(5,720.86)**	**(395.17)**
C. Cash flow from financing activities		
Proceeds from issue Non-convertible debentures	5,310.00	-
Proceeds of long-term borrowings	68.05	94.24
Repayment of long-term borrowings	(61.07)	(54.46)
Repayment of borrowings for purchase of capital asset	(0.80)	(0.32)
Proceeds of borrowings for purchase of capital asset	0.40	0.45
Interest and processing charges paid	(58.33)	(35.79)
Interest paid on loan for purchase of capital asset	(0.13)	(0.16)
Payment of lease obligations	(10.99)	(11.72)
Interest paid on lease liabilities	(65.90)	(60.29)
Net cash generated from / (used in) financing activities	**5,181.23**	**(68.05)**
Net (decrease)/ increase in cash and cash equivalents	**(10.56)**	**4.27**
Cash and cash equivalents at the beginning of the year	65.21	60.94
Cash and cash equivalents at the end of the year (refer note 9.3)	**54.65**	**65.21**
Components of cash and cash equivalents for the purpose of cash flow statement		
Cash on hand	0.78	1.37
With banks - on current accounts	53.87	33.84
- deposits with original maturity of less than three months	-	30.00
Total cash and cash equivalents	**54.65**	**65.21**

Refer Note 38 for Reconciliation of movement of liabilities to cash flows arising from financing activities

Material accounting policies 2.2

The above Cash flow statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard-7, "Statement of Cash Flows"

The accompanying notes are an integral part of standalone financial statements

As per our report of even date attached

For B S R & Co. LLP

Chartered Accountants
Firm Registration number : 101248W/W - 100022

Prakash

G Prakash
Partner
Membership number: 099696

Place : Bengaluru
Date : May 22, 2026

For and on behalf of the Board of Directors of
Manipal Hospitals Private Limited

H Sudarshan Ballal

Dr. H. Sudarshan Ballal
Chairman

Deepak Venugopalan
Chief Executive Officer

Pratik Gupta
Chief Financial Officer

K. G. Vahora

Khadija G Vahora
Company Secretary
Membership number: A37266

Place : Bengaluru
Date : May 22, 2026

1 Corporate information

Manipal Hospitals Private Limited ("the Company") was established in the year 2003 and commissioned its first operating hospital in the year 2005. The Company is a private limited company incorporated under the provisions of the Companies Act of India. The registered office of the Company is located at The Annexe, #98/2, Rustam Bagh Road, HAL Airport Road, Bengaluru, 560017. The Company operates through various Hospitals/Clinics providing Healthcare services in India. The Company is a wholly owned subsidiary of Manipal Health Enterprises Limited ("MHEL") (formerly known as Manipal Health Enterprises Private Limited)

2.1 Basis of preparation of the Standalone Financial Statements

(a) Statement of compliance

The Standalone Financial Statements of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, notified under section 133 of the Companies Act, 2013 ('Act') and other relevant provisions of the Act.

The Standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest crores and decimals thereof, except when otherwise indicated.

The Standalone Financial Statements were approved for issue by the Company's Board of Directors on May 22, 2026

Details of the material accounting policies are included in Note 2.2

(b) Going Concern

During the year ended March 31, 2026, the Company reported a net current liability position of ₹ 304.41 crores mainly on account of interest accrued as at March 31, 2026 amounting to ₹ 264.05 crores on its 9.03% non-convertible debentures (NCDs) payable in September 2026 and consideration due in December 2026 for acquisition of 9.84% stake in Sahyadri Hospitals Private Limited ("SHPL") amounting to ₹ 574.05 crores and the Company's debt-equity ratio stood at 4.12:1. These events or conditions cast significant doubts on the Company's ability to continue as a going concern. Management has evaluated these matters, together with the Company's expected cash flows from operations, availability of existing debt investments for liquidation if required, the corporate guarantee provided by the Holding Company for the NCDs, and the unconditional support letter from the Holding Company confirming operational and financial support as necessary. Based on this assessment, management believes that the Company will be able to meet its liabilities as they fall due in the normal course of business and that preparation of the financial statements on a going concern basis remains appropriate.

(c) Functional and presentation currency

These Standalone Financial Statements are presented in Indian Rupees (₹), which is also the Company's functional currency. All amounts are in Indian Rupees (₹) crores and decimals thereof, except share data and per share data, unless otherwise stated

(d) Basis of measurement

The Standalone Financial Statements have been prepared on accrual and going concern basis and the historical cost basis except for the following items:

Items	Measurement
Certain financial assets and liabilities (Refer note 33)	Fair value
Net defined asset / liability	Fair value of plan asset less present value of defined benefit obligation

(e) Use of estimates and judgments

In preparing these Standalone Financial Statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

Judgments, assumptions and estimation uncertainties

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognised in the financial statements is included in the following notes.

Judgements:-

Note 13.2 - Determining the lease term of contracts with renewal and termination options

Estimates (including assumptions):-

Note 2.2 (c), (d) and (g) - useful life of property, plant and equipment, intangible assets and right of use assets
Note 2.2 (a), 5.1, 5.3, 9.1, 9.5 - Impairment of financials assets and Investment in subsidiaries
Note 6, 14, 19 and 30 - Recognition of deferred tax, provisions and other contingencies
Note 17 - Provisions
Note 23, 32 - Employee benefits expense, wages and bonus; key actuarial assumptions
Note 33 - Financial instruments

(f) Measurement of fair values

The Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.
Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

– Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities
– Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
– Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values is included in the note 33 – financial instruments.

2.2 Summary of material accounting policies

(a) Investment in subsidiaries

A subsidiary is an entity that is controlled by another entity. The investments in subsidiaries are carried at cost as per IND AS 27. Investment carried at cost is tested for impairment as per IND AS 36. On disposal of investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss (refer note 5.1)

(b) Current versus non-current classification

Based on the time involved between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has identified twelve months as its operating cycle for determining current and non-current classification of assets and liabilities in the Standalone Financial Statement

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

(c) Property plant and equipment

Property, plant and equipment including capital work in progress is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, import duties, cost of replacing part of the plant and equipment, borrowing costs if the recognition criteria are met and directly attributable cost of bringing the asset to its location and condition necessary for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in statement of profit and loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the company and the cost of the item can be measured reliably

Property, plant and equipment under installation or construction as at the balance sheet date is shown as capital work-in-progress and the related advances are shown as under Non current assets.

On transition to Ind AS (i.e. April 01, 2014), the Company has elected to continue with the carrying value of all Property, plant and equipment measured as per the previous GAAP and use that carrying value as the deemed cost of Property, plant and equipment.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows.

Category of assets	Useful life estimated by management	Useful life as per Schedule II
Buildings	23 - 30 years	30 years
Other fixtures (included in Buildings)	2 years	10 years
Equipments	13 years	10 - 15 years
Facility and office equipment	7 years	10 years
Furniture and fixtures	7 years	10 years
Computers	3 years	3 - 6 years
Vehicles	3-7 years	6 - 10 years
Electrical installations	7 years	10 years

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (up to) the date on which asset is ready for use (disposed of).

Second hand assets are depreciated over the estimated useful life as per technical estimates.

Leasehold land/Leasehold improvements/Leasehold Building are depreciated over the primary lease period or useful life, whichever is shorter, on a straight-line basis.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each period end and adjusted prospectively, if appropriate.

Assets having the value upto ₹10,000 is fully depreciated in the period/year of purchase.

The management has estimated, supported by technical assessment, the useful life of the category of assets, which are lower than those indicated in Schedule II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used.

(d) Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any.

The useful lives of intangible assets are assessed as either finite or indefinite.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

Intangible assets with indefinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in statement of profit and loss as incurred.

There are no internally generated intangible assets capitalised by the Company.

A summary of amortization policies applied to the Company's intangible assets is as below:

Category of assets	Useful life estimated by management
Computer software - application	3-5 years
Computer software - generic	1 year

(e) Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long term growth rate is calculated and applied to project future cash flows till perpetuity.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs.

Impairment losses of continuing operations, including impairment of inventories, are recognised in the statement of profit and loss.

For all assets, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit and loss.

Intangible assets with indefinite useful lives are tested for impairment annually at each balance sheet date and as at 31 March at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.

(f) Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

(g) Leases

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Company as a lessee

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset. Right of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently re-measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and re-measuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in statement of profit and loss.

The Company applies the short-term lease recognition exemption to short term leases of all assets that have a lock in lease term of 12 months or less, except where it anticipates renewals and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

Company as a lessor

At the inception of the lease the Company classifies each of its leases as either an operating lease or a finance lease. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant periodic rate of return on the lessor's net investment in the lease

If an arrangement contains lease and non-lease components, the Company applies Ind AS 115 Revenue from contracts with customers to allocate the consideration in the contract.

(h) Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets
Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price determined under Ind AS 115. Refer to the accounting policies in section (i) Revenue from contracts with customers.

In order for a financial asset to be classified and measured at amortised cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Company's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows while financial assets classified and measured at fair value through OCI are held within a business model with the objective of both holding to collect contractual cash flows and selling

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:
i) Financial assets at amortised cost (debt instruments)
ii) Financial assets at fair value through other comprehensive income (FVTOCI) with recycling of cumulative gains and losses (debt instruments)
iii) Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments)
iv) Financial assets at fair value through profit or loss

Financial assets at amortised cost (debt instruments)
A 'financial asset' is measured at the amortised cost if both the following conditions are met:
a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss. The losses arising from impairment are recognised in the profit or loss. The Company's financial assets at amortised cost includes trade receivables. For more information on receivables, refer to note 9.2.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the balance sheet at fair value with net changes in fair value recognised in the statement of profit and loss.

This category includes derivative instruments and listed equity investments which the Company had not irrevocably elected to classify at fair value through OCI. Dividends on listed equity investments are recognised in the statement of profit and loss when the right of payment has been established

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:
i) The rights to receive cash flows from the asset have expired, or
ii) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

Impairment of financial assets

The Company recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL)

For trade receivables, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment

In certain cases, the Company may also consider a financial asset to be in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Financial liabilities
Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and financial guarantee contracts.

Subsequent measurement
For purposes of subsequent measurement, financial liabilities are classified in two categories:
• Financial liabilities at fair value through profit or loss
• Financial liabilities at amortised cost (loans and borrowings)

Financial liabilities at fair value through profit or loss
Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments

Gains or losses on liabilities held for trading are recognised in the profit or loss

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/ losses are not subsequently transferred to P&L. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the statement of profit and loss. The Company has not designated any financial liability as at fair value through profit or loss.

Financial liabilities at amortised cost (Loans and borrowings)
This is the category most relevant to the Company. After initial recognition, interest-bearing loans, borrowings and other financial liabilities are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings.

Derecognition
A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments
Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

(i) Inventories

Inventories of pharmacy items and medical consumables are valued at lower of cost or net realizable value. The comparison of cost and net realizable value is made on an item by item basis. Cost of these inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for Goods and Services Tax (GST) wherever applicable, applying the first in first out basis

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs to be incurred to make the sale. Adequate provision is made for slow moving, non-moving and expired inventory, as determined necessary.

(j) Non-current assets held for sale
Non-current assets are classified as held for sale if it is highly probable that they will be recovered primarily through sale rather than through continuing use. Such assets, are generally measured at the lower of their carrying amount and fair value less costs to sell.

Non-current assets classified as held-for-sale are presented separately from the other assets in the balance sheet.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

(k) Total income

(i) Revenue recognition

Revenue from contracts with customers is recognised as per Ind AS 115, "Revenue from contract with customers", when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services, taking into consideration defined terms of payment and excluding taxes or duties collected on behalf of the government.

Disaggregation of revenue

The Company disaggregates revenue into revenue from rendering hospital services, pharmacy sales and other operating income. The Company believes that this disaggregation best depicts how the nature, amount, timing and uncertainty of Company's revenues and cash flows are affected by industry, market and other economic factors.

Operating Income

Revenue from Hospital services is recognised as and when the services are performed, unless significant future uncertainties exists, while revenue from sale of pharmacy items is recognised when the control of the goods have passed to the buyer, usually on delivery of the goods. The Company assesses the distinct performance obligations in the contract and measures to at an amount that reflects the consideration it expects to receive, net of Goods and Services Tax and adjusted for discounts and concessions.

Management fee from hospital management agreement with entities is recognised as and when the services are rendered as per the terms of the agreement.

Income from occupational health centre and ambulance service are recorded as and when rendered.

Rental Income

Rental Income is recognised on an accrual basis and over the year of tenancy.

Contract balances

Trade receivables

Unbilled revenue represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in section (i) Financial instruments – initial recognition and subsequent measurement.

Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Company performs its obligation under the contract.

(ii) Other income

Interest Income

For all debt instruments measured at amortised cost, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension) but does not consider the expected credit losses. Interest income is included in finance income in the statement of profit or loss.

Dividend income

Dividend income is recognized when the Company's right to receive dividend is established by the reporting date.

(l) Foreign currencies

Items included in the Standalone Financial Statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency") The Company's financial statements are presented in INR, which is also the Company's functional and presentation currency.

Transactions and balances

Foreign currency transactions are recorded on initial recognition in the functional currency using the exchange rate prevailing at the date of the transaction. However, for practical reasons, the Company uses an average rate if the average approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on the settlement or translation of monetary items are recognised in the statement of profit and loss.

(m) Retirement and other employee benefits

Defined contribution plan

Retirement benefit in the form of Provident Fund and Pension Fund are defined contribution schemes. The Company recognizes contribution payable to the schemes as an expense, when an employee renders the related service. The Company has no obligation, other than the contribution payable to the fund.

Defined benefit plan- gratuity

The Company operates a defined benefit plan for its employees for gratuity. The costs of providing benefits under this plan is determined on the basis of actuarial valuation at each year end using the projected unit credit method.

Remeasurements, comprising of actuarial gains and losses, excluding amounts included in net interest on the net defined benefit liability, are recognised immediately in the balance sheet with a corresponding debit or credit through OCI in the period in which they occur. Remeasurements are not reclassified to the statement of profit and loss in subsequent periods.

Past service costs are recognised in the statement of profit and loss on the earlier of :
- The date of the plan amendment or curtailment and
- The date that the Company recognises related restructuring costs

Interest is calculated by applying the discount rate to the defined benefit liability. The Company recognises the following changes in the defined benefit obligation as an expense in the statement of profit and loss:
(i) Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements and
(ii) Interest expense

Other long-term employee benefits - compensated absences

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. The Company presents the entire leave as a current liability in the balance sheet, since it does not have an unconditional right to defer its settlement beyond 12 months after the reporting date.

The Company recognizes termination benefit as a liability and an expense when the group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the termination benefits fall due more than 12 months after the balance sheet date, they are measured at present value of future cash flows using the discount rate determined by reference to market yields at the balance sheet date on government bonds.

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

(n) **Taxes**

Current income tax
Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in accordance with the Income Tax Act, 1961 enacted in India. The tax rates and tax laws used to compute the amounts are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax
Deferred tax is provided on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date
Deferred tax liabilities are recognised for all taxable temporary differences except:
- where deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:
- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the statement of profit or loss is recognised outside the statement of profit or loss (either in OCI or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and to the same taxation authority.

Goods and Services Tax (GST) paid on acquisition of assets or on incurring expenses

Expenses and assets are recognised net of the amount of GST paid, except:

When the tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable

When receivables and payables are stated with the amount of tax included, the net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

(o) **Earnings Per Share (EPS)**

Basic EPS amounts are calculated by dividing the net profit/(loss) for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit/(loss) for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period adjusted for treasury shares held. Diluted earnings per share is computed using the weighted-average number of equity and dilutive equivalent shares outstanding during the period, using the treasury stock method for options and warrants, except where the results would be antidilutive.

(p) **Provisions**

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit or loss net off any reimbursement

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

Onerous contracts
A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

(q) **Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the Standalone Financial Statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

(r) **Cash and cash equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

(s) **Segment accounting policies**

The Company prepares its segment information based on its reporting to Chief Operating Decision Maker (refer note 36 on segment reporting).

(t) **Corporate Social Responsibility (CSR) expenditure**

CSR expenditure as per provisions of section 135 of Companies Act, 2013 read with The Companies (Corporate Social Responsibility Policy) Rules, 2014, is charged to the statement of profit and loss as an expense as and when incurred.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

(u) Cash flow statement

Cash flows are reported using the indirect method, whereby net profit/ (loss) before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity's cash management.

(v) Share capital

Equity shares
Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

(w) New and amended standards

(i) Amendments to Ind AS 21 - Lack of exchangeability
The Ministry of Corporate Affairs (MCA) notified the Companies (Indian Accounting Standards) Amendment Rules, 2025, which amend Ind AS 21, The Effects of Changes in Foreign Exchange Rates to specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows.
The amendments are effective for annual reporting periods beginning on or after April 01, 2025. When applying the amendments, an entity cannot restate comparative information.
The amendments do not have a material impact on the Company's financial statements.

(ii) Amendments to Ind AS 1 - Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants
The Ministry of Corporate Affairs notified amendments to paragraphs 69 to 76 of Ind AS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:
- What is meant by a right to defer settlement
- That a right to defer must exist at the end of the reporting period
- That classification is unaffected by the likelihood that an entity will exercise its deferral right
- That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification

In addition, a requirement has been introduced to require disclosure when a liability arising from a loan agreement is classified as non-current and the entity's right to defer settlement is contingent on compliance with future covenants within twelve months.
If there is a breach of a material covenant of a long term loan arrangement on or before the end of the reporting period, resulting in the liability becoming payable on demand as at the reporting date, and the lender agrees—after the reporting period but before the financial statements are approved for issue—not to demand repayment for at least 12 months as a consequence of the breach, this shall be treated as an adjusting event. Accordingly, the entity is not required to classify the liability as current.
The amendments are effective for annual reporting periods beginning on or after April 01, 2026 retrospectively in accordance with Ind AS 8.
The amendment does not have a material impact on the Company's Financial Statements.

(iii) Amendments to Ind AS 7 and Ind AS 107 - Supplier Finance Arrangements
In August 2025, the MCA notified amendments to Ind AS 7 Statement of Cash Flows and Ind AS 107 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.
The amendments are not expected to have a material impact on the Company's Financial Statements.

(iv) Amendments to Ind AS 12 - International Tax Reform—Pillar Two Model Rules
In August 2025, the MCA notified amendments to Ind AS 12 Income Taxes in response to the OECD's BEPS Pillar Two rules and include:
- A mandatory temporary exception to the recognition and disclosure of deferred taxes arising from the jurisdictional implementation of the Pillar Two model rules; and
- Disclosure requirements for affected entities to help users of the financial statements better understand an entity's exposure to Pillar Two income taxes arising from that legislation, particularly before its effective date

The mandatory temporary exception – the use of which is required to be disclosed – applies immediately. The remaining disclosure requirements apply for annual reporting periods beginning on or after 1 April 2025, but not for any interim periods ending on or before 31 March 2026.
The amendments are not expected to have a material impact on the Company's Financial Statements.

(This space has been intentionally left blank)

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

3.1 Property, plant and equipment

(₹ in crores)

	Land	Leasehold land	Leasehold Improvements	Buildings	Equipments	Facility and office equipment	Furniture and fixtures	Computers	Vehicles	Electrical installations	Total
Cost											
At April 01 , 2024	72.47	18.63	147.42	373.23	503.33	120.13	45.59	61.37	3.36	112.65	1,458.18
Additions	-	-	7.10	4.45	70.08	-	5.74	11.34	1.31	8.49	108.51
Disposals/ adjustments	-	-	(0.07)	(2.40)	(8.08)	(7.67)	(3.23)	(4.12)	(0.21)	(0.09)	(25.87)
At March 31 , 2025	72.47	18.63	154.45	375.28	565.33	112.46	48.10	68.59	4.46	121.05	1,540.82
Additions	-	-	0.22	6.66	65.52	-	3.50	5.81	1.08	12.27	95.06
Disposals/ adjustments	-	-	-	(0.18)	(1.20)	(6.78)	(0.32)	(0.83)	(0.63)	(1.41)	(11.35)
At March 31 , 2026	72.47	18.63	154.67	381.76	629.65	105.68	51.28	73.57	4.91	131.91	1,624.53
Depreciation											
At April 01 , 2024	26.98	-	12.17	160.81	264.46	112.17	39.52	44.67	0.78	70.21	731.77
Charge for the year	-	-	6.67	11.51	33.44	4.40	3.17	10.87	0.58	10.36	81.00
Disposals/ adjustments	-	-	(0.07)	(2.23)	(7.39)	(7.66)	(3.23)	(4.06)	(0.20)	(0.08)	(24.92)
At March 31 , 2025	26.98	-	18.77	170.09	290.51	108.91	39.46	51.48	1.16	80.49	787.85
Charge for the year	-	-	6.42	11.82	37.27	1.60	2.77	10.85	0.72	9.91	81.36
Disposals/ adjustments	-	-	-	(0.09)	(0.87)	(6.72)	(0.32)	(0.81)	(0.28)	(1.41)	(10.50)
At March 31 , 2026	26.98	-	25.19	181.82	326.91	103.79	41.91	61.52	1.60	88.99	858.71
Net book value											
At March 31 , 2025	45.49	18.63	135.68	205.19	274.82	3.55	8.64	17.11	3.30	40.56	752.97
At March 31 , 2026	45.49	18.63	129.48	199.94	302.74	1.89	9.37	12.05	3.31	42.92	765.82

Refer note 13.1 for details of Property, plant and equipment provided as security for borrowings.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

3.2 Capital Work-in-progress

(₹ in crores)

	Total
Cost	
At April 01, 2024	9.66
Additions during the year	112.18
Transferred to Property, plant and equipment	(108.51)
At March 31, 2025	**13.33**
Additions during the year	144.08
Transferred to Property, plant and equipment	(95.06)
At March 31, 2026	62.35

Capital work in progress ageing schedule

As at March 31, 2026 (₹ in crores)

Particulars	Amount in CWIP for a period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	51.53	10.82	-	-	62.35
Total	**51.53**	**10.82**	-	-	**62.35**

There are no material capital work-in-progress for which the completion is overdue or has exceeded its cost compared to its original budget.

As at March 31, 2025 (₹ in crores)

Particulars	Amount in CWIP for a period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	13.33	-	-	-	13.33
Total	13.33	-	-	-	13.33

There are no material capital work-in-progress for which the completion is overdue or has exceeded its cost compared to its original budget.
Refer note 13.1 for details of Capital Work-in-progress provided as security for borrowings.

3.3 Assets held for sale

(₹ in crores)

	March 31, 2026	March 31, 2025
Land	6.50	6.50
	6.50	**6.50**

(3.3.1) Land held for sale pertains to vacant land situated at Meerut ₹ 6.50 crores (March 31, 2025: ₹ 6.50 crores)
(3.3.2) As of March 31, 2026, the Company is actively responding to evolving market conditions and ongoing infrastructure developments in and around Meerut. Efforts to market the land are ongoing, with the aim of achieving optimal realisation through a potential sale.

4.1 Right of use assets

(₹ in crores)

	Right-of-use assets					
	Leasehold land & building *	Equipments	Vehicles	Computers	Electrical installations	Total
Cost						
At April 01, 2024	**498.34**	**12.06**	**0.68**	**15.76**	-	**526.84**
Additions	3.09	-	-	-	15.67	18.76
Disposals/adjustments	(2.35)	-	-	-	-	(2.35)
At March 31, 2025	**499.08**	**12.06**	**0.68**	**15.76**	**15.67**	**543.25**
Additions	2.12	13.97	-	3.04	2.50	21.63
Disposals/adjustments	-	-	-	(11.21)	(2.31)	(13.52)
At March 31, 2026	**501.20**	**26.03**	**0.68**	**7.59**	**15.86**	**551.36**
Depreciation						
At April 01, 2024	**104.56**	**10.05**	**0.68**	**7.58**	-	**122.87**
Charge for the year	21.47	0.50	-	5.56	1.67	29.20
Disposals/adjustments	(1.95)	-	-	-	-	(1.95)
At March 31, 2025	**124.08**	**10.55**	**0.68**	**13.14**	**1.67**	**150.12**
Charge for the year	21.79	0.71	-	2.54	2.26	27.30
Disposals/adjustments	-	-	-	(10.94)	(0.43)	(11.37)
At March 31, 2026	**145.87**	**11.26**	**0.68**	**4.74**	**3.50**	**166.05**
Net book value						
At March 31, 2025	**375.00**	**1.51**	-	**2.62**	**14.00**	**393.13**
At March 31, 2026	**355.33**	**14.77**	-	**2.85**	**12.36**	**385.31**

* Refer note 13.1 for details of assets provided as security for borrowings

4.2 Intangible assets

	(₹ in crores)
	Intangible assets
	Computer software*
Cost	
At April 01, 2024	**80.42**
Additions	4.92
Disposals	(0.02)
At March 31, 2025	**85.32**
Additions	7.96
At March 31, 2026	**93.28**
Amortisation	
At April 01, 2024	**42.11**
Charge for the year	15.43
Disposals	(0.02)
At March 31, 2025	**57.52**
Charge for the year	12.74
At March 31, 2026	**70.26**
Net book value	
At March 31, 2025	**27.80**
At March 31, 2026	**23.02**

*Refer note 13.1 for details of Intangible assets provided as security for borrowings.

5 Non-current financial assets

5.1 Investments

(₹ in crores)

	No of units		Amounts	
	March 31, 2026	**March 31, 2025**	**March 31, 2026**	**March 31, 2025**
Investments carried at cost (unquoted)				
A) Investment in equity shares of subsidiary company				
Manipal Hospitals (East) India Private Limited ("MHEIPL") (formerly known as AMRI Hospitals Private [shares of ₹ 10 each fully paid-up, refer note 5.1.1]	12,24,98,744	5,71,12,194	710.61	396.00
Sahyadri Hospitals Private Limited ("SHPL") @ [shares of ₹ 10 each fully paid-up, refer note 5.1.4]	2,99,25,153	-	5,793.09	-
(A)			**6,503.70**	**396.00**
B) Investment in Compulsory convertible debentures ("CCD") of subsidiary company MHEIPL [refer note 5.1.1]	-	850	-	314.57
(B)			-	**314.57**
Aggregate value of unquoted investments carried at cost (A+B)			**6,503.70**	**710.57**
Investments at fair value through Profit and Loss				
Investments in other companies (unquoted)				
Manipal Hospitals Synergie Private Limited ('MHSPL') (formerly known as 'Medica Synergie Private Limited') [shares of ₹ 10 each fully paid-up]	1	-	0.00*	-
O2 Renewable Energy X Private Limited				
-Equity shares of ₹ 10 each fully paid up	1,15,900	1,15,900	0.12	0.12
-Compulsory convertible debentures of ₹ 1,000 each [Refer note 5.1.2]	10,424	10,424	1.04	1.04
Atria Wind Power (Basavana Bagewadi) Private Limited				
-Equity shares of ₹ 100 each fully paid up	1,26,000	1,000	2.44	0.02
[Refer note 5.1.3] (C)			**3.60**	**1.18**
* Represents value less than ₹ 0.01 crore				
Investments in mutual funds (quoted) #^ (D)			138.66	18.65
Aggregate value of investments carried at fair value through Profit and Loss (C+D)			**142.26**	**19.83**
Aggregate value of investments (A+B+C+D)			**6,645.96**	**730.40**
Aggregate value of provision for impairment				

Information about the company's exposure to fair value measurement and credit and market risks, is included in note 33 & 34
Refer note 13.1 for details of Investments provided as security for borrowings.
^ The Company has created a lien in favour of the debenture trustee towards mutual fund amounting to ₹ 118.06 crores as at March 31, 2026.

5.1.1 On September 20, 2023 the Company along with its affiliates, acquired 5,71,12,194 equity shares and 850 compulsorily convertible debentures of MHEIPL from existing shareholders. Further, on June 30, 2025, the Company acquired an additional 2,000 equity shares from existing shareholders amounting to ₹ 0.04 crores. The Company's shareholding in MHEIPL is 84.07% on a fully diluted basis. During the year ended March 31, 2026, the Company converted 850 compulsorily convertible debentures of MHEIPL into 6,53,84,550 equity shares of ₹ 10 each.

5.1.2 On October 23, 2023, the Company subscribed to 1,15,900 equity shares and 10,424 Series B compulsory convertible debentures of O2 Renewable Energy X Private Limited as captive power consumer.

5.1.3 On January 16, 2025 the Company has invested an amount of ₹ 0.02 crores in Atria Wind Power (Basavana Bagewadi) Private Limited by purchasing 1,000 equity shares as captive power consumer. Further, during the year ended March 31, 2026, the Company had invested an additional amount of ₹ 2.42 crores for 1,25,000 equity shares.

5.1.4 In the month of October 2025, the Company acquired controlling stake of 78.71% shareholding in Sahyadri Hospitals Private Limited ('SHPL') for a consideration of ₹ 4,596.55 crores. The Company had the commitment to purchase 3,271,954 additional shares (9.84%) under Tranche 2 by December 01, 2025 and 3,271,960 shares (9.84%) under Tranche 3 by December 01, 2026, subject to fulfilment of necessary conditions as defined under the Share Purchase Agreement. The Company had acquired Tranche 2 shares on December 01, 2025 for a consideration of ₹ 574.44 crores. The Company had a commitment to purchase 1.47% shareholding from minority shareholder of SHPL, the shares from minority shareholders were acquired in the month of October 2025 and December 2025 to the extent of 1.43% at a total consideration of ₹ 83.86 crores. Pursuant to the Debenture Trust Deed dated September 8, 2025, the Company has created pledge over its investment in Sahyadri Hospitals Private Limited within 120 days from date of acquisition. This condition was satisfied by the Company on January 23, 2026 vide execution of Pledge Agreement in favour of the Debenture Trustee.

@ Investments are tested for impairment when circumstances indicate that the carrying value may be impaired. Impairment is determined by assessing the recoverable amount of each investment. When the recoverable amount of the investment is less than its carrying amount, an impairment loss is recognized. The recoverable amounts of the above investments have been assessed using a value-in-use model. Key assumptions upon which the Company has based its determinations of value-in-use include :

a) Estimated cash flows based on internal budgets and industry outlook for a period of thirteen years and a terminal growth rate thereafter for SHPL.
- The estimated value-in-use of this investment is based on the future cash flows using a 5.00% annual growth rate for periods subsequent to the forecast period of 13 years. This long term growth rate takes into consideration external macroeconomic sources of data. Such long-term growth rate considered does not exceed that of the relevant business and industry sector
- Pre-tax Discount rate of 14.20% which reflect current market assessment of the risks.
The Company believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

5.2 Loans (Unsecured considered good unless otherwise stated)

(₹ in crores)

	March 31, 2026	March 31, 2025
Inter Corporate Deposit given to related parties (refer note 5.2.1 and 29)	-	12.76
Less: Interest accrued on inter corporate deposits to related parties - disclosed under other non-current financial assets (refer note	-	(0.35)
	-	12.41

* Refer note 13.1 for details of Loans pledged as security for borrowings.

5.2.1 Term of the loan as given below:

(₹ in crores)

Name of the loanee	Rate of Interest	Repayment	Secured/ unsecured	March 31, 2026	Movement during the year	March 31, 2025
MHEIPL						
Inter Corporate Deposit ("ICD")	8.50%	Thirty-Six	Unsecured	-	(12.76)	12.76

(₹ in crores)

Name of the loanee	Rate of Interest	Repayment	Secured/ unsecured	March 31, 2026	Movement during the year	March 31, 2025
SHPL						
Inter Corporate Deposit ("ICD")	8.50%	Thirty-Six months	Unsecured	-	*	-

The intercorporate deposit has been made available to MHEIPL and SHPL for the purpose of meeting its general corporate requirements.

*During the year ended March 31, 2026, the Company had given inter-corporate deposit to SHPL amounting to ₹ 50.00 crores and the same was repaid along with interest during the current period.

Provisions of section 186 of the Companies Act, 2013, except sub section (1), are not applicable, as the Company is engaged in the business of providing infrastructural facilities as specified in Schedule VI of the Companies Act, 2013.

5.3 Other financial assets (Unsecured considered good unless otherwise stated)

(₹ in crores)

	March 31, 2026	March 31, 2025
Margin money deposit with banks (refer note 5.3.1)	0.40	0.60
Deposits with banks due to mature after twelve months from the reporting date (refer note 5.3.2)	7.77	7.23
Interest accrued on ICD to related parties (refer note 5.3.3)	-	0.35
Security deposits	18.90	17.42
	27.07	25.60

(5.3.1) Margin money deposits with a carrying amount of ₹ 0.40 crores (March 31, 2025: ₹ 0.60 crores) are provided as bank guarantee.

(5.3.2) It includes Debt Service Reserve Account maintained by the company with Banks amounting to ₹ 7.77 crores (March 31, 2025 : ₹ 7.23 crores)

(5.3.3) Receivable from related parties (refer note 29)

6 Income tax assets (net)

(₹ in crores)

	March 31, 2026	March 31, 2025
Income tax assets (net of provision for income tax)	73.92	11.25
	73.92	11.25

7 Other non-current assets (Unsecured considered good unless otherwise stated)

(₹ in crores)

	March 31, 2026	March 31, 2025
Capital advances		
Considered good	0.08	0.37
Considered doubtful	17.88	17.88
	17.96	18.25
Less: Provision for doubtful capital advances	(17.88)	(17.88)
	0.08	0.37
Prepaid expenses	0.66	0.43
Balances with government authorities	17.77	17.64
Defined benefit plan assets (refer note 32)	0.31	1.68
	18.82	20.12

8 Inventories (valued at lower of cost and net realizable value)

(₹ in crores)

	March 31, 2026	March 31, 2025
Pharmacy items	17.12	13.43
Medical consumables	19.23	17.94
	36.35	31.37

Refer note 13.1 for details of Inventories provided as security for borrowings

BSR & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

9 **Current financial assets**

9.1 **Investments**

(₹ in crores)

	March 31, 2026	March 31, 2025
Investments at fair value through Profit and Loss		
Investments in mutual funds (quoted)	653.47	399.07
Aggregate market value of quoted investments	**653.47**	**399.07**

Information about the company's exposure to fair value measurement and credit and market risks, is included in note 33 & 34
Refer note 13.1 for details of Investments provided as security for borrowings

9.2 **Trade receivables (Unsecured considered good unless otherwise stated)**

(₹ in crores)

	March 31, 2026	March 31, 2025
Considered good	189.04	128.75
Less: Loss allowance on trade receivables	(28.30)	(19.28)
	160.74	**109.47**

Refer note 13.1 for details of Trade receivables provided as security for borrowings.
(9.2.1) There are no trade receivables which have significant increase in credit risk.
(9.2.2) Ageing for trade receivables and unbilled revenue due from the due date for each of the category is as follows:

As at March 31, 2026 (₹ in crores)

Particulars	Outstanding for following periods from due date of payment						
	Not due*	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables - considered good	95.13	82.23	10.54	0.45	0.63	0.06	189.04
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade receivable - credit impaired	-	-	-	-	-	-	-
Disputed Trade receivables - considered good	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-
Total	**95.13**	**82.23**	**10.54**	**0.45**	**0.63**	**0.06**	**189.04**
Expected credit allowance %	-	**20.50%**	**97.68%**	**100.00%**	**100.00%**	**100.00%**	**14.97%**

* includes unbilled revenue of ₹ 16.05 crores as considered good.

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment						
	Not due*	Less than 6 Months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed Trade Receivables - considered good	70.09	48.65	7.63	2.32	0.06	-	128.75
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade receivable - credit impaired	-	-	-	-	-	-	-
Disputed Trade receivables - considered good	-	-	-	-	-	-	-
Disputed Trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade receivables - credit impaired	-	-	-	-	-	-	-
Total	**70.09**	**48.65**	**7.63**	**2.32**	**0.06**	-	**128.75**
Expected credit allowance %	-	**19.98%**	**94.10%**	**100.00%**	**100.00%**	-	**14.97%**

* includes unbilled revenue of ₹ 14.23 crores as considered good.

9.3 **Cash and cash equivalents**

(₹ in crores)

	March 31, 2026	March 31, 2025
Balances with banks:		
- On current accounts	53.87	33.84
- Deposits with original maturity of less than three months	-	30.00
Cash on hand	0.78	1.37
Total cash and cash equivalents	**54.65**	**65.21**

Refer note 13.1 for details of Cash and cash equivalents provided as security for borrowings

9.4 **Loans (Unsecured considered good unless otherwise stated)**

(₹ in crores)

	March 31, 2026	March 31, 2025
Loans to employees	0.13	0.26
	0.13	**0.26**

There are no loans which have significant increase in credit risk nor which are credit impaired
Refer note 13.1 for details of Loans provided as security for borrowings.

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

9.5 Other financial assets (Unsecured considered good unless otherwise stated)

(₹ in crores)

	March 31, 2026	March 31, 2025
Margin money deposit with banks	12.05	11.10
Interest accrued on fixed deposits	0.41	0.42
Other receivables (refer note 9.5.1)		
Considered good	0.72	0.60
Considered doubtful	0.38	0.28
Less: Loss allowance on Other receivable	(0.38)	(0.28)
Net other receivables	0.72	0.60
Security deposits	0.19	0.40
	13.37	**12.52**

(9.5.1) includes receivables from related parties (refer note 29)

Refer note 13.1 for details of Other financial assets provided as security for borrowings.

10 Other current assets (Unsecured considered good unless otherwise stated)

(₹ in crores)

	March 31, 2026	March 31, 2025
Prepaid expenses	6.32	5.52
Advances to suppliers	2.92	3.68
Balance with government authorities	0.96	1.35
	10.20	**10.55**

Refer note 13.1 for details of Other current assets provided as security for borrowings.

(This space has been intentionally left blank)

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

11 Equity Share capital

(₹ in crores)

	March 31, 2026	March 31, 2025
11.1 Authorised shares (Nos.)		
1,104,950,000 (March 31, 2025: 1,104,950,000) Equity shares of ₹ 10/- each	1,104.95	1,104.95
11.2 Issued, subscribed and fully paid-up shares (Nos.)		
1,025,297,268 (March 31, 2025: 1,025,297,268) Equity Shares of ₹ 10/- each	1,025.30	1,025.30
Total issued, subscribed and fully paid-up share capital	**1,025.30**	**1,025.30**

11.3 Reconciliation of the number of equity shares outstanding at the beginning and at the end of the reporting year:

	March 31, 2026		March 31, 2025	
	Nos.	(₹ in crores)	Nos.	(₹ in crores)
At the beginning of the year	1,02,52,97,268	1,025.30	1,02,52,97,268	1,025.30
Add : Issued during the year	-	-	-	-
At the end of the year	**1,02,52,97,268**	**1,025.30**	**1,02,52,97,268**	**1,025.30**

11.4 Terms/rights attached to equity shares

The Company has only one class of equity shares having par value of ₹ 10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The final dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. During the year, the Company has not declared any dividend.

In the event of liquidation of the Company, the holders of equity shares would be entitled to receive remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to number of equity shares held by shareholders.

11.5 Shares held by holding company

	March 31, 2026		March 31, 2025	
	Nos.	(₹ in crores)	Nos.	(₹ in crores)
Manipal Health Enterprises Limited*	1,02,52,97,268	1,025.30	1,02,52,97,268	1,025.30

*Includes 10,000 (March 31,2025: 10,000) equity shares of ₹ 10 each held by nominee director on behalf of the holding company.

11.6 Details of shareholders holding more than 5% shares in the company:

	March 31, 2026		March 31, 2025	
	Number of shares	% holding in the class	Number of shares	% holding in the class
Equity shares of ₹ 10 each fully paid				
Manipal Health Enterprises Limited	1,02,52,97,268	100.00%	1,02,52,97,268	100.00%

As per the records of the Company, including its register of shareholders/ members and other declaration received from shareholders regarding beneficial interest, the above shareholding represent both legal and beneficial ownership of shares.

11.7 Details of shareholding by the promoter of the company

As at March 31, 2026

Promoter Name	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Manipal Health Enterprises Limited	1,02,52,97,268	-	1,02,52,97,268	100.00%	0.00%
	1,02,52,97,268	-	**1,02,52,97,268**	**100.00%**	**0.00%**

As at March 31, 2025

Promoter Name	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Manipal Health Enterprises Limited	1,02,52,97,268	-	1,02,52,97,268	100.00%	0.00%
	1,02,52,97,268	-	**1,02,52,97,268**	**100.00%**	**0.00%**

11.8 There have been no issue of bonus shares, buy back of shares, issue of shares for consideration other than cash for the period of five years immediately preceding the balance sheet date.

11.9 As at March 31, 2026 and March 31, 2025, the Company does not have any shares reserved for issue under options and contracts or commitments for the sale of shares

12 Other equity

(₹ in crores)

	March 31, 2026	March 31, 2025
12.1 Securities premium		
Balance at the beginning of the year	246.89	246.89
Add: Addition during the year	-	-
Balance at the end of the year	**246.89**	**246.89**
12.2 Re-measurement of defined benefit plan		
Balance at the beginning of the year	(1.12)	(0.10)
OCI for the year (net of tax)	0.59	(1.02)
Balance at the end of the year	**(0.53)**	**(1.12)**
12.3 Retained earnings		
Balance at the beginning of the year	38.67	(292.55)
Add: Profit for the year	205.94	331.22
Less: Transfer from amalgamation adjustment deficit account on account of surplus in retained earnings	(59.11)	-
Less: Transferred to Debenture redemption reserve	(185.50)	-
Balance at the end of the year	-	**38.67**
12.4 Debenture redemption reserve		
Balance at the beginning of the year	-	-
Add: Transferred from retained earnings	185.50	-
Balance at the end of the year	**185.50**	-
12.5 Amalgamation adjustment deficit account		
Balance at the beginning of the year	(59.11)	(59.11)
Add: Transferred from retained earnings	59.11	-
Balance at the end of the year	-	**(59.11)**
Total of other equity	**431.86**	**225.33**

BSR & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

13 **Non-current financial liabilities**

13.1 **Borrowings (secured unless other-wise stated)**

(₹ in crores)

		March 31, 2026	March 31, 2025
Borrowings			
Term loan from banks (refer note 13.1.1 & 13.1.2)		396.16	388.15
Term loan from financial institutions (refer note 13.1.1 & 13.1.2)		78.62	79.32
Non-convertible debentures (refer note 13.1.3 & 13.1.4)		5,261.84	-
Loan for purchase of capital asset (refer note 13.1.5 & 13.1.6)		1.59	1.99
	(A)	5,738.21	469.46
Less: Current maturities - disclosed under the head 'short term borrowings'			
Term loan from banks		66.46	60.37
Term loan from financial institutions		1.59	0.70
Loan for purchase of capital asset		0.38	0.40
	(B)	68.43	61.47
Non- Current Borrowings	(A-B)	5,669.78	407.99

13.1.1 **Details of Principal outstanding, rate of interest and repayment terms for term loans from banks and financial institutions**

As at March 31, 2026

Particulars	Interest Rate as on March 31, 2026	Frequency	Number of structured installements	Year of Maturity	Principal Outstanding (net of transaction cost) (₹ in crores)
Secured Term loan (Bank 1)	7.08%	Quarterly	Upto 38 Installments	June 30, 2028	47.19
Secured Term loan (Bank 2)	7.12%	Quarterly	Upto 36 Installments	June 30, 2028	37.06
Secured Term loan (Bank 3)	7.15%	Quarterly	Upto 48 Installments	June 30, 2034	183.86
Secured Term loan (Bank 4)	7.25%	Quarterly	Upto 40 Installments	March 31, 2036	60.00
Secured Term loan (Bank 5)	7.22%	Quarterly	Upto 58 Installments	December 31, 2040	68.05
Secured Term loan (Financial institution 1)	7.85%	Quarterly	Upto 80 Installments	December 31, 2044	78.62
Total					**474.78**

As at March 31, 2025

Particulars	Interest Rate as on March 31, 2025	Frequency	Number of structured installements	Year of Maturity	Principal Outstanding (net of transaction cost) (₹ in crores)
Secured Term loan (Bank 1)	8.19%	Quarterly	Upto 38 Installments	June 30, 2028	69.58
Secured Term loan (Bank 2)	8.25%	Quarterly	Upto 36 Installments	June 30, 2028	54.48
Secured Term loan (Bank 3)	8.15%	Quarterly	Upto 48 Installments	June 30, 2034	204.09
Secured Term loan (Bank 4)	8.25%	Quarterly	Upto 40 Installments	March 31, 2036	60.00
Secured Term loan (Financial instituion 1)	8.25%	Quarterly	Upto 80 Installments	December 31, 2044	79.32
Total					**467.47**

13.1.2 **The terms and conditions of all the term loans from banks and financial institutions are similar and are as follows:**
During the year ended March 31, 2026 and March 31, 2025, the Company entered into facility agreement with its lenders and offered consolidated security as below:-
a) A first ranking pari passu security interest over all movable fixed assets and current assets of the Company along with Manipal Health Enterprises Limited ("MHEL"), Manipal Hospitals (East) India Private Limited ("MHEIPL"), Manipal Hospitals (Dwarka) Private Limited ("MHDPL") and Manipal Hospitals (Bengaluru) Private Limited ("MHBPL") including but not limited to movable plant and machinery, machinery spares, tools and accessories, furniture, fixtures, intangible assets (including goodwill, trademarks and patents) and all other movable properties of whatsoever nature (both present and future) (other than any debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to the facilities) as per the facility agreement;
b) A first ranking pari passu security interest over specific immovable properties of the Company, MHEL, MHEIPL and MHDPL
c) A first ranking pari passu security interest, by way of hypothecation, over all leasehold improvements of all immovable properties and excluded properties.
d) Exclusive security interest over the debt service reserve amounts (including in the form of fixed deposits or lien marked mutual funds) or debt service reserve accounts required to be maintained or maintained with respect to such facility.

13.1.3 **Details of Principal outstanding, rate of interest and repayment terms for Non-convertible debentures**

	March 31, 2026	March 31, 2025
Principal outstanding (₹ in crores)	5,261.84	-
Rate of interest	9.03%	-
Year of repayment	2027	-

13.1.4 **Terms of Non-convertible debentures**
MHPL has issued 531,000 denominated, senior, unsecured, rated and listed nonconvertible debentures, having a face value of ₹ 100,000 each. The coupon rate for the NCDs was determined at 9.03%. The NCDs are backed by corporate guarantee from MHEL. Pursuant to the Debenture Trust Deed dated September 8, 2025, MHPL has created pledge over its investment in Sahyadri Hospitals Private Limited within 120 days from date of acquisition. This condition was satisfied by the Company on January 23, 2026 vide execution of Pledge Agreement in favour of the Debenture Trustee.

13.1.5 **Details of Principal outstanding, rate of interest and repayment terms for loan for purchase of capital asset**

	March 31, 2026	March 31, 2025
Principal outstanding (₹ in crores)	1.59	1.99
Rate of interest	(7.35% to 8.00%)	(8.35% to 9.15%)
Year of repayment	2027 to 2031	2027 to 2031

13.1.6 The Company obtained vehicle under financing arrangements from Bank and secured against such vehicle.

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

13.2 Lease liabilities

(₹ in crores)

	March 31, 2026	March 31, 2025
Opening balance	585.85	569.51
Add: New leases during the year	21.56	18.70
Add: Interest accrued	74.00	70.11
Less: Interest paid	(65.90)	(60.29)
Less: Lease paid	(10.99)	(11.72)
Less: Lease termination/adjustments	(2.15)	(0.46)
	602.37	**585.85**
Non-current	588.31	574.16
Current	14.06	11.69

The Company had total cash outflows for short term leases and low value leases of March 31, 2026: ₹ 25.64 crores (March 31,2025: ₹ 22.18 crores).

13.2.1 Notes

The Company has taken on lease certain land and building for hospital operations, hostels for staff, equipment, office spaces and vehicles for use in the course of its business.

Refer notes 2.2(g) in relation to accounting policy for leases.

Refer note 4.1 for depreciation charge for right-of-use assets by class of underlying asset and additions to right-of-use assets and the carrying amount of right-of-use assets at the end of the reporting period by class of underlying asset.

Refer note 26.1 in relation to short term leases and leases of low-value assets accounted for applying paragraph 6 of Ind AS 116.

Refer note 34C disclosure on maturity analysis of lease payments

Refer note 38 disclosure on cash outflows for leases liabilities

13.3 Other financial liabilities

(Rs. in crore)

	March 31, 2026	March 31, 2025
Other financial liability carried at fair value	5.61	-
	5.61	-

14 Income Tax

The major components of income tax expense for the year ended March 31, 2026 and March 31, 2025 are:

(₹ in crores)

	March 31, 2026	March 31, 2025
Statement of Profit and loss:		
Current income tax:		
Current year income tax charge	70.11	119.59
Adjustment of tax relating to earlier years	(0.62)	(3.48)
	69.49	**116.11**
Deferred tax :		
Origination and reversal of temporary differences	(0.13)	(1.79)
Tax expense reported in the statement of profit or loss	**69.36**	**114.32**
OCI section		
Tax on net loss on remeasurement of defined benefit plan	0.20	(0.33)
Tax credit reported in OCI	**0.20**	**(0.33)**

Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate:

(₹ in crores)

	March 31, 2026	March 31, 2025
Profit before tax	275.30	445.54
Statutory income tax rate of 25.17% (March 31, 2025: 25.17%)	69.29	112.13
Tax effect of non-deductible expenses	1.60	1.18
Impact of statutory tax rate changes on capital gains	-	4.22
Tax adjustment pertaining to earlier years	(0.62)	(3.48)
Others	(0.91)	0.27
	69.36	**114.32**

Deferred tax

(₹ in crores)

	Recognised in balance sheet		Recognised in profit and loss and other comprehensive income	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
Property plant equipment and Intangible assets: Impact of difference between tax depreciation as per Income Tax Act, 1961 over depreciation/ amortization as per Companies Act, 2013.	(148.24)	(150.17)	(1.92)	(0.60)
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis * #	161.36	155.86	(5.50)	(3.72)
Allowance for bad and doubtful debts	7.22	4.92	(2.30)	(1.27)
Fair valuation of investments in mutual funds	(7.68)	(4.08)	3.60	3.38
Others	3.84	10.03	6.19	0.09
Deferred tax expense (credit)			**0.07**	**(2.12)**
Net deferred tax assets	**16.50**	**16.56**		

* Includes items under 43B such as Leave encashment, gratuity, bonus.

\# Gratuity amount routed through other comprehensive income pertaining to remeasurement of defined benefit plan

Reflected in the balance sheet as follows:

(₹ in crores)

	March 31, 2026	March 31, 2025
Deferred tax assets	172.42	170.81
Deferred tax liabilities	(155.92)	(154.25)
Deferred tax assets (net)	**16.50**	**16.56**

Deferred tax liabilities has not been recognised on temporary differences in relation to investment in subsidiary's gross investment value amounting to ₹ 6,503.70 crore (March 31, 2025: ₹ 710.57 crore), as the Company is able to control the timing of the reversal of the temporary difference and it is probable that the temporary differences will not reverse in foreseeable future.

B S R & Co. LLP

Manipal Hospitals Private Limited ★ Bengaluru

15 Current financial liabilities

15.1 Borrowings (Short term)

(₹ in crores)

	March 31, 2026	March 31, 2025
Term loan from banks (refer note 13.1.1 & 13.1.2)	66.46	60.37
Term loan from financial institutions (refer note 13.1.1 & 13.1.2)	1.59	0.70
Loan for purchase of capital asset (refer note 13.1.5 & 13.1.6)	0.38	0.40
Interest accrued but not due on borrowings (refer note 13.1)	0.04	-
Interest accrued but not due on non convertible debentures (refer note 13.1.3 & 13.1.4)	264.05	-
	332.52	61.47

15.2 Trade payables

(₹ in crores)

	March 31, 2026	March 31, 2025
Trade payables		
- total outstanding dues of micro enterprises and small enterprises*	8.86	6.11
- total outstanding dues of creditors other than micro enterprises and small enterprises	283.65	268.89
	292.51	275.00

*Also refer note 41

(15.2.1) For details relating to payable to related parties refer note 29

(15.2.2) There were no disputed dues from Micro enterprises and small enterprises and other creditors

As at March 31, 2026 (₹ in crores)

Particulars	Outstanding for following periods from due date of payment					
	Not due (Including provision for expense)	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Total outstanding dues of micro enterprises and small enterprises	7.50	1.36	-	-	-	8.86
Total outstanding dues of creditors other than micro enterprises and small enterprises	241.68	35.18	1.59	2.28	2.92	283.65
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total	**249.18**	**36.54**	**1.59**	**2.28**	**2.92**	**292.51**

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payment					
	Not due (Including provision for expense)	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Total outstanding dues of micro enterprises and small enterprises	5.82	0.29		-	-	6.11
Total outstanding dues of creditors other than micro enterprises and small enterprises	226.73	33.19	2.82	3.85	2.30	268.89
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total	**232.55**	**33.48**	**2.82**	**3.85**	**2.30**	**275.00**

16 Other financial liabilities

(₹ in crores)

	March 31, 2026	March 31, 2025
Interest accrued but not due on borrowings (refer note 16.1.1)	-	0.06
Capital creditors (refer note 16.1.2)	23.37	20.67
Sundry deposits	0.37	0.33
Retention money	3.20	1.50
Other financial liability carried at fair value (refer note 16.1.3)	538.42	-
	565.36	22.56

(16.1.1) The details of interest rates, repayment and other terms are disclosed under note 13.1

(16.1.2) As at March 31, 2026, outstanding amount of ₹ 1.99 crores (March 31, 2025: ₹ 1.20 crores) is due to micro and small enterprises. There are no interest due or outstanding on the same. There were no amounts paid to micro and small enterprises beyond the due date during the current and the previous years.

(16.1.3) Includes amount attributable towards Tranche 3 for acquisition of SHPL.

17 Provisions

(₹ in crores)

	March 31, 2026	March 31, 2025
Current		
Provision for employee benefits		
Provision for compensated absences	11.33	13.07
	11.33	13.07

18 Other current liabilities

(₹ in crores)

	March 31, 2026	March 31, 2025
Statutory dues	12.39	10.86
Advance received from customer (refer note 18.1.1)	5.15	9.31
	17.54	20.17

(18.1.1) Refer note 20 (b)

19 Current tax liabilities (net)

(₹ in crores)

	March 31, 2026	March 31, 2025
Current tax liabilities (net of advance tax)	-	1.78
	-	1.78

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

20 Revenue from operations

(₹ in crores)

	March 31, 2026	March 31, 2025
Revenue from goods and services *		
Hospital services	2,411.55	2,129.36
Pharmacy sales	107.77	84.58
Less: Discounts #	(64.37)	(76.91)
Total revenue from contract with customers (A)	**2,454.95**	**2,137.03**
Other operating revenues		
Occupational health centre and ambulance service	10.87	10.52
Management fees from hospitals	2.94	-
Rental income	2.15	2.33
Parking charges	0.83	0.91
Others	2.56	2.96
Total (B)	**19.35**	**16.72**
Total (A+B)	**2,474.30**	**2,153.75**

* includes transactions with related parties (refer note 29)
# primarily from hospital services

a) The revenue from contracts with customer at disaggregation is provided above.
b) Changes in contract liabilities- Advance received from customers

(₹ in crores)

	March 31, 2026	March 31, 2025
Balance at the beginning of the year	**9.31**	**8.12**
Less: Revenue recognised that was included in the balance at the beginning of the year	(9.31)	(8.12)
Add: Increase due to advance from patients received, net of unbilled revenue (refer note 18)	5.15	9.31
Balance at the end of the year	**5.15**	**9.31**
Expected revenue recognition from remaining performance obligations:		
- Within one year	5.15	9.31

c) Contract balances

(₹ in crores)

	March 31, 2026	March 31, 2025
Receivables		
- Trade receivables (refer note 9.2)	160.74	109.47
Contract liabilities		
- Advance received from customer (refer note 18)	5.15	9.31

Unbilled revenue is relating to the service rendered where the invoicing is not done and Trade receivable are non-interest bearing and are generally on a terms of 30 to 120 days

Contract liabilities relates to the advances received from the customers to deliver the hospital service. There is no significant changes in the contract liabilities during the year.

d) Timing of revenue recognition

(₹ in crores)

	March 31, 2026	March 31, 2025
Revenue recognised over the time	1,890.07	1,680.40
Revenue recognised at a point in time	629.25	533.54
Less: Discounts	(64.37)	(76.91)
Total revenue from contracts with customers	2,454.95	2,137.03

21 Other income

(₹ in crores)

	March 31, 2026	March 31, 2025
Profit on sale of investments in mutual funds (net)	12.32	3.48
Fair value gain on financial instruments at FVTPL	26.49	13.57
Profit on sale of property, plant and equipment (net)	0.46	0.78
Interest income:-		
- on inter corporate deposit *	2.34	3.82
- on financial assets at amortised cost	0.89	0.82
- on bank deposits	21.41	1.46
- on income tax refund	-	1.43
- on defined benefit obligation (net) (refer note 32)	0.06	-
	63.97	**25.36**

* includes transactions with related parties (refer note 29)

22 Changes in inventories of medical consumables and pharmacy items

(₹ in crores)

	March 31, 2026	March 31, 2025
Pharmacy items		
Inventory at the beginning of the year	13.43	13.01
Less: Inventory at the end of the year	(17.12)	(13.43)
	(3.69)	(0.42)
Other medical consumables		
Inventory at the beginning of the year	17.94	14.26
Less: Inventory at the end of the year	(19.23)	(17.94)
	(1.29)	(3.68)
	(4.98)	**(4.10)**

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

23 Employee benefits expense *

	March 31, 2026	March 31, 2025
	(₹ in crores)	
Salaries, wages and bonus	241.17	216.90
Contribution to provident and other funds (refer note 32)	15.84	14.27
Gratuity expenses (refer note 32)	3.77	3.04
Staff welfare expenses	8.91	6.76
	269.69	240.97

* includes transactions with related parties (refer note 29)

24 Finance costs

	March 31, 2026	March 31, 2025
	(₹ in crores)	
Bank charges	6.45	9.86
Interest		
- on bank loan	35.01	35.57
- on defined benefit obligation (refer note 32)	-	0.54
- on leases	74.00	70.11
- on vehicle loan	0.13	0.16
- on self-assessment tax	0.03	0.01
- on non-convertible debentures	264.05	-
- on other financial liability carried at fair value	24.04	-
Loan processing fees		
- on financial liabilities measured at amortised cost	18.74	0.64
Total interest expense	**416.00**	**107.03**
Total finance costs	**422.45**	**116.89**

25 Depreciation and amortisation expense

	March 31, 2026	March 31, 2025
	(₹ in crores)	
Depreciation of property, plant and equipment (refer note 3.1)	81.36	81.00
Depreciation of right of use assets (refer note 4.1)	27.30	29.20
Amortisation of intangible assets (refer note 4.2)	12.74	15.43
	121.40	125.63

26 Other expenses

	March 31, 2026	March 31, 2025
	(₹ in crores)	
Doctors professional fees	600.86	515.05
House keeping, including consumables	31.03	26.04
Power and fuel and other utilities	34.99	35.07
Security charges	14.07	13.38
Rent (refer note 26.1)	25.64	22.18
Contractual manpower	76.05	62.33
Rates and taxes	1.70	3.09
Insurance	2.20	3.98
Repairs and maintenance		
- Buildings	2.08	1.59
- Plant and machinery	22.98	19.06
- Others **	47.20	36.14
Corporate social responsibility (refer note 37)	6.37	4.59
Advertising and sales promotion**	80.55	80.39
Travelling and conveyance	5.50	8.16
Communication costs	1.75	1.61
Printing and stationery	7.72	6.59
Legal and professional fees**	18.81	21.72
Directors sitting fees	0.01	-
Payment to auditors	2.15	0.89
Bad debts/advances written off	13.25	16.07
Loss allowance on trade receivables (net of reversals)	9.05	4.76
Loss allowance on other receivables (net of reversals)	0.11	0.10
Foreign exchange loss (net)	0.64	0.98
Miscellaneous expenses	2.80	3.18
	1,007.51	886.95

** includes transactions with related parties (refer note 29)

26.1 Represents amounts incurred by the Company towards expenses relating to short-term leases, leases of low-value assets and ineligible GST on lease payments written off. Also refer note 2.2(g).

26.2 Payment to auditors*

	March 31, 2026	March 31, 2025
	(₹ in crores)	
Audit fees	2.15	0.89
	2.15	0.89

*Amount inclusive of Goods and Service Tax (GST).

B S R & Co. LLP

Manipal Hospitals Private Limited ★ Bengaluru

27 Exceptional items

(i) The Company has incurred certain project fees, legal and professional fees towards its business expansion amounting to ₹ 12.30 crores. The Company has disclosed the same as exceptional item in the Financial Statements.

(ii) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws.

The Company has assessed the financial implications of these changes, based on the best available information and in line with guidance provided by the Institute of Chartered Accountants of India, which has resulted in increase of provision for employee benefits by ₹ 4.27 crores. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Statement of standalone financial results for the year ended March 31, 2026.

The Company continues to monitor the finalisation of relevant rules and clarifications from the Government on all aspects of the labour codes and would accordingly take necessary steps for compliance thereof and also provide appropriate accounting effect on the basis of such developments, as needed.

(iii) The Company has agreed for a discretionary one-time incentive to certain employees in recognition of their contribution to the Company's growth. The incentive is subject to a clawback condition linked to continued employment, as per the terms of the agreement. The Company has recognised expense of ₹ 0.19 crores for the amortised portion of incentive cost for the year ended March 31, 2026.

28 Earnings per share (EPS)

The following reflects the income and share data used in the basic and diluted EPS computations:

(₹ in crores)

	March 31, 2026	March 31, 2025
Profit attributable to the equity shareholders for basic EPS	205.94	331.22
Weighted average number of equity shares	1,02,52,97,268	1,02,52,97,268
Earnings per share - Basic and diluted - ₹	2.01	3.23

29 Related party transactions

(a) Names of related parties where control exists irrespective of whether transactions have occurred or not:

Holding Company	- Manipal Health Enterprises Limited ('MHEL') (formerly known as Manipal Health Enterprises Private Limited)
Subsidiary	- Manipal Hospitals (East) India Private Limited ('MHEIPL') (formerly known as AMRI Hospitals Private - Sahyadri Hospitals Private Limited ('SHPL')
Stepdown Subsidiary	- Sahyadri Karad Hospitals Private Limited ('Karad Hospitals') - Surya Hospitals Private Limited ('Surya Hospitals') - Saideep Healthcare and Research Private Limited ('Saideep')

(b) Names of other related parties as per Ind AS 24:

Fellow subsidiaries	- Manipal Hospitals (Dwarka) Private Limited ('MHDPL') - Manipal Hospitals (Bengaluru) Private Limited ('MHBPL') - Healthmap Diagnostics Private Limited - Manipal Hospitals Eastern India Private Limited ('MH Eastern') (formerly known as Medica Hospitals Private Limited) - Manipal Hospitals Bengal Private Limited (formerly known North Bengal Clinic Private Limited)
Other related parties (Enterprise over which Key management personnel ("KMP") of holding company has significant influence)	- ManipalCigna Health Insurance Company Limited - MEMG International India Private Ltd - UNext Learning Private Limited - Manipal Academy of Higher Education - Manipal Foundation
Key management personnel	- Dr. H. Sudarshan Ballal, Director - Mr. Karthik Rajagopal, Director - Mr. Sameer Agarwal, Director - Mr. Vinesh Kumar Jairath, Director (w.e.f February 12, 2026) - Mr. Mohan Kumar, Director (w.e.f February 12, 2026) - Ms. Mangala Rohith, Director (w.e.f February 12, 2026)

(c) Names of additional related parties as per Companies Act, 2013:

Chief Executive Officer	- Mr. Deepak Venugopalan (w.e.f February 12, 2026)
Chief Financial Officer	- Mr. Pratik Gupta (w.e.f February 12, 2026)
Company Secretary	- Ms. Khadija G Vahora

Transactions with the above related parties during the year ended:

(₹ in crores)

Name of related party	Nature of transaction	March 31, 2026	March 31, 2025
Remuneration to key management personnel (KMP)	Employee Benefits	0.22	0.20
Manipal Health Enterprises Limited (formerly known as Manipal Health Enterprises Private Limited)	Hospital Services received	8.35	9.85
	Hospital Services rendered	3.75	2.28
	Purchase of medical pharmacies/consumables (net of returns)	7.54	1.80
	Sale of medical pharmacies/consumables (net of returns)	0.17	0.26
	Reimbursement of Expenses incurred on behalf of the Company	270.90	225.23
	Recovery of expenses incurred on behalf of other Company	10.87	3.16
	Corporate guarantee received	26.55	-
	Amount received from related party #	2.11	20.00
	Amount paid to related party #	295.16	262.04

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

Manipal Academy of Higher Education	Hospital Services rendered	0.76	1.11
	Amount received from related party #	0.66	1.19
ManipalCigna Health Insurance Company Limited	Insurance expenses	-	2.34
	Amount received from related party #	0.11	-
Manipal Hospitals (Dwarka) Private Limited	Recovery of expenses incurred on behalf of the related party	0.60	0.13
	Reimbursement of Expenses incurred on behalf of the Company	-	0.04
	Hospital Services rendered	0.00*	-
	Purchase of medical pharmacies/consumables (net of returns)	0.00*	-
	Amount received from related party #	0.56	0.11
MEMG International India Private Ltd	Royalty charges / back-office charges (included under legal and professional expense)	11.62	10.77
Manipal Foundation	Corporate Social Responsibility Expenditure	6.37	4.59
	Amount paid to related party #	6.37	4.59
Manipal Hospitals (Bengaluru) Private Limited	Sale of medical pharmacies/consumables (net of returns)	0.07	-
	Purchase of asset	0.03	0.04
	Purchase of medical pharmacies/consumables (net of returns)	0.00*	0.08
	Amount paid to related party #	2.07	3.36
	Hospital Services rendered	1.10	1.37
	Hospital Services received	-	0.00*
	Reimbursement of expenses incurred on behalf of the Related party	3.51	3.64
	Recovery of expenses incurred on behalf of the related party	0.11	0.07
Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited)	ICD given during the year	321.70	314.90
	ICD repayment received the year	334.11	335.95
	Interest Income received on ICD	1.78	4.54
	Interest Income on ICD	1.60	3.82
	Purchase of medical pharmacies/consumables (net of returns)	5.95	0.11
	Sale of medical pharmacies/consumables (net of returns)	0.11	0.04
	Amount paid to related party #	13.10	0.68
	Amount received from related party #	3.27	0.02
	Reimbursement of expenses incurred on behalf of the Company	1.27	0.29
	Recovery of expenses incurred on behalf of the related party	0.06	0.59
	Conversion of CCD into equity shares during the year	85.00	-
	Hospital Services rendered	0.55	0.18
	Hospital Services received	3.76	1.83
UNext Learning Private Limited	Hospital Services rendered	-	0.02
	Amount received from related party #	0.02	0.01
Healthmap Diagnostics Private Limited	Diagnostic services received	0.88	0.80
Manipal Hospitals Eastern India Private Limited (formerly known as Medica Hospitals	Hospital Services rendered	0.40	-
	Hospital Services received	0.37	-
	Purchase of medical pharmacies/consumables (net of returns)	0.01	-
	Sale of medical pharmacies/consumables (net of returns)	0.02	-
	Reimbursement of expenses incurred on behalf of the Company	0.01	-
	Recovery of expenses incurred on behalf of the related party	0.00*	-
Manipal Hospital Bengal Private Limited (formerly known North Bengal Clinic Private Limited)	Purchase of medical pharmacies/consumables (net of returns)	0.00*	-
	Reimbursement of expenses incurred on behalf of the Company	0.00*	-
	Hospital service rendered	0.00*	
	Amount received from related party #	0.00*	-
Sahyadri Hospitals Private Limited	Hospital service rendered	0.02	-
	ICD given during the year	50.00	-
	ICD repayment received the year	50.00	-
	Interest Income received on ICD	0.67	-
	Interest Income on ICD	0.75	-
	Hospital services received	0.44	-
	Amount paid to related party #	0.38	-
	Amount received from related party #	0.01	-

* Represents value less than ₹ 0.01 crore

Amount paid to related party/amount received from related party represents amounts remitted or received towards settlement of related party transactions (as detailed in the table above)

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

Balances receivable from/payable to related parties are as follows:

(₹ in crores)

Name of related party	Nature of balances	March 31, 2026	March 31, 2025
Manipal Health Enterprises Limited (formerly known as Manipal Health Enterprises Private Limited)	Trade Payables	4.03	7.03
ManipalCigna Health Insurance Company Limited	Advance to Suppliers	-	0.11
Manipal Foundation	Advance to Suppliers	-	0.07
Manipal Hospitals (Dwarka) Private Limited	Other receivables	0.05	0.01
MEMG International India Private Limited	Trade Payables	1.44	4.32
Manipal Academy of Higher education	Other receivables	0.15	0.18
Manipal Hospitals (Bengaluru) Private Limited	Trade Payables	0.83	0.56
Manipal Hospitals (East) India Private Limited (formerly known as AMRI Hospitals Private Limited)	ICD receivable	-	12.41
	Interest accrued on ICD	-	0.35
	Trade Payables	0.73	0.84
UNext Learning Private Limited	Other receivables	0.00*	0.02
Healthmap Diagnostics Private Limited	Trade payables	0.29	0.01
Manipal Hospital Eastern India Private Limited	Other receivables	0.00*	-
Manipal Hospital Bengal Private Limited	Trade Payables	0.00*	-
Sahyadri Hospitals Private Limited	Trade payables	0.21	-

* Represents value less than ₹ 0.01 crore

Terms and conditions of transactions with related parties

The sales/purchases, income/expenses, loans from/to related parties are made on terms equivalent to those that prevail in arm's length transactions. During the current and previous years, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken during each financial year through examining the financial position of the related party and the market in which the related party operates.

(This space has been intentionally left blank)

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

30 Contingent liabilities

(₹ in crores)

	March 31, 2026	March 31, 2025
(A) Claims against the Company not acknowledged as debts		
i) Patient Compensation	1.84	2.41
ii) Indirect Tax		
Goods and Service Tax	0.12	17.26
Finance Act, 1994	11.40	11.40
(B) Guarantees #	2.31	0.21
	15.67	**31.28**

includes performance guarantees

(i) Patient Compensation

There are certain claims made against the Company in respect of patient compensation. The cases are pending with various Consumer Disputes Redressal Commissions. Based on the legal counsel's views, the management does not expect these claims to succeed. Accordingly, no provision for liability has been recognized in the Standalone Financial Statements.

The Company is confident that its position will be upheld for above litigations.

(ii) Indirect Tax Demand

Goods and Service Tax

(a) During the year 2016-17, while filing TRAN-1- Transitional ITC for CENVAT Credit and Value assed Tax (VAT) credit, the Company has inadvertently claimed SGST credit in TRANS-1 amounting to ₹ 0.47 crores while there was no VAT credit available to be transitioned to Goods and Service Tax (GST). Upon realizing its mistake, the Company has voluntarily remitted back the same amount. Subsequently, the department issued notice for difference in credit claimed as per Tran 1 and VAT returns and has demanded interest of ₹ 0.07 crores and penalty of ₹ 0.05 crores as applicable under KGST Act. The Company has thereafter made payment of the interest in 2021. Considering the above fact, that the Company has already remitted the impugned amount even before the authorities identified along with the interest, the company believes it has a good case and the penalty imposed would be set aside.

Finance Act, 1994

(a) Commissioner, Central Tax (Audit-1, Commissionerate) has issued show cause notice number 54/2020-21 CTA-1/Commr. dated December 30, 2020 towards non-reversal of Cenvat credit/non-payment of Service Tax payable under provisions of Rule 6 of the Cenvat Credit Rules, 2004 in respect of exempted services for the period from October 1, 2014 to June 30, 2017 for an amount of ₹ 10.10 crores including interest and penalty. The Company has remitted the tax amount of ₹ 3.55 crores under protest and filed response to the notice before the Principal Commissioner/ Commissioner of Central Tax, East Commissionerate on February 26, 2021.The authorities vide Order-in-Original number 57/2021 dated November 30, 2021 confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company has filed the appeal with CESTAT on April 18, 2022

(b) Deputy Commissioner, Circle IV, Central Tax (Audit-1, Commissionerate) has issued show cause notice number 47/2020-21 CTA-1/Dy Commr. dated December 18, 2020 towards non-payment of Service Tax under reverse charge on services received from Director of the Company payable under Section 68(2) of the Finance Act, 1994 for an amount of ₹ 1.30 crores including interest and penalty. The Company has filed its response to the show cause notice before the Deputy/Assistant Commissioner of Central Tax East division -5, Bangalore East Commissionerate on January 18, 2021. The authorities vide Order-in-Original number 199/2022 dated March 31, 2022 confirmed the aforesaid demand including interest and penalty. Aggrieved by the impugned order, the Company has filed the appeal with Commissioner of Service Tax(Appeals) on June 16, 2022 and remitted the tax amount of ₹ 0.31 crores under protest.

Based on the discussions, the Company had with the tax experts, they are of the view that the Company has good case on merits and has higher probability of winning the above cases, both under GST and Finance Act. Accordingly, it has been disclosed as a contingent liability.

Pending resolution of the respective proceedings, it is not practicable for the company to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

(iii) The Company along with MHEL, MHBPL, MHDPL and MHEIPL have provided security to various lenders in the form of first ranking pari passu charge over Immovable properties including lease hold improvements, Movable Fixed Assets, Intangibles assets and Current Assets (as defined in the Facility Agreements) for the term loans amounting to ₹ 4,930.63 crores (March 31 2025: ₹ 4,663.53 crores) availed by the Company, MHEL, MHBPL, MHDPL, HCMCT (Silo), MHEIPL and MH Eastern.

31 Capital Commitments and other commitments

As at March 31, 2026, the company has a commitment towards purchase of capital asset of ₹ 67.42 crores (March, 31 2025: ₹ 73.67 crores).

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

32 Employee benefit plan

(i) Defined contribution plan:
Amount recognised and included in note 23, Contribution to provident and other funds in statement of profit and loss of ₹ 15.84 crores (March 31, 2025: ₹ 14.27 crores)

(ii) Defined benefit plan:
The Company has a defined benefit gratuity plan. Under this plan, every employees who are entitled as per the Gratuity Act, gets a gratuity on departure at 15 days of last drawn salary for each completed year of service. The gratuity plan is a funded plan and the Company makes contributions to funds maintained with an insurance company.

The following tables summarize the components of net benefit expense recognized in the statement of profit and loss and amounts recognized in the balance sheet.

(₹ in crores)

	March 31, 2026	March 31, 2025
a) Statement of profit and loss and other comprehensive income		
i) Net employee benefit expense recognized in the statement of profit or loss		
Current service cost	3.77	3.04
Interest cost on benefit obligation	1.09	0.90
Past service cost disclosed under exceptional item (refer note 27)	1.54	-
Expected return on plan assets	(1.16)	(0.36)
Net benefit expense charged to statement of profit or loss	**5.24**	**3.58**
ii) Remeasurement		
Actuarial changes arising from changes in:		
-Financial assumptions	(0.86)	0.75
-Demographic assumptions	-	0.29
-Experience adjustments	(0.63)	0.43
Return on plan assets excluding interest income	0.70	(0.12)
Total amount recognised in other comprehensive income	**(0.79)**	**1.35**
b) Balance Sheet		
Net defined benefit asset		
Non current	(0.31)	(1.68)
Current	-	-
Plan asset	**(0.31)**	**(1.68)**
c) Change in projected benefit obligations		
Defined benefit obligation at the beginning of the year	(1.68)	7.71
Fair value of plan assets at the beginning of the year	17.60	5.04
Current service cost	3.77	3.04
Past service cost	1.54	-
Interest cost	1.09	0.90
Benefits paid	(1.30)	(1.55)
Remeasurement of gain in other comprehensive income		
Actuarial changes arising from changes in:		
-Financial assumptions	(0.86)	0.75
-Demographic assumptions	-	0.29
-Experience adjustments	(0.63)	0.43
Liabilities settled on account of intergroup transfer	0.21	(0.69)
Fair value of plan assets at the end of the year	(20.05)	(17.60)
Obligations at end of the year	**(0.31)**	**(1.68)**
d) Movements in the fair value of plan assets are as follows		
Fair value of plan assets at the beginning of the year	17.60	5.04
Interest income	1.16	0.36
Actuarial gain/(loss) on plan assets	(0.70)	0.12
Contribution paid into the plan	3.29	13.63
Benefits paid	(1.30)	(1.55)
Fair value of plan assets at the end of the year	**20.05**	**17.60**

Defined plan asset

Plan assets consist of assets held in a "long-term benefit fund" for the sole purpose of making future benefit payments when they fall due. Plan assets include qualifying insurance policies and are not quoted in the market.

	March 31, 2026	March 31, 2025
e) Investment details of plan assets:		
Insurer managed funds	20.05	17.60
	20.05	**17.60**

The Company expects to pay ₹ 3.00 crore in contributions to its defined benefit plans in 2026-27

f) The principal assumptions used in determining gratuity liability for the Company's plan are shown below:

Discount rate	7.15%	6.70%
Increase in compensation cost	6.00%	6.00%
Retirement Age	60 years	60 years

Employee turnover

Age (Years) March 31, 2026	Rate (p.a.) March 31, 2026	Age (Years) March 31, 2025	Rate (p.a.) March 31, 2025
21 - 30	24.63%	21 - 30	24.63%
31 - 34	10.17%	31 - 34	10.17%
35 - 44	8.34%	35 - 44	8.34%
45 - 50	2.87%	45 - 50	2.87%
51 - 54	1.63%	51 - 54	1.63%
55 - 59	3.92%	55 - 59	3.92%

Mortality rates are as per Indian Assured lives Mortality (2012-14) Ult [March 31, 2025: Indian Assured lives Mortality (2012-14) Ult.]

The estimates of future salary increases, considered in actuarial valuation take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market

Sensitivity analysis
Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation as shown below:

	March 31, 2026		March 31, 2025	
	0.5% Increase	0.5% Decrease	0.5% Increase	0.5% Decrease
Discount rate	(4.50%)	4.87%	(4.70%)	5.09%
Future salary growth	4.90%	(4.57%)	5.10%	(4.75%)

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

Maturity profile of defined benefit obligation:

(₹ in crores)

	March 31, 2026	March 31, 2025
Within 1 year	1.72	1.19
Between 2 and 5 years	7.20	5.29
Between 6 and 10 years	6.09	5.05
Beyond 10 years	30.90	24.39

The average duration of the defined benefit planned obligations at the end of the reporting period is 9.36 years (March 31, 2025 : 9.78 years)

(This space has been intentionally left blank)

33 Fair values and hierarchy

Accounting classification and fair value of financial instruments is as follows. The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair value:
- The fair value of the quoted mutual funds are at Level 1 of Fair value hierarchy and are measured based on Net Asset Value (NAV) in active markets at the reporting date.

- The fair value of the financial assets (other than mutual funds) and financial liabilities were based on amortised cost at the reporting date.

The following table provides the fair value measurement hierarchy of financial assets and liabilities of the Company:

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2026:

(₹ in crores)

March 31, 2026	Level 1	Level 2	Level 3	Total
Financial assets (at FVTPL)				
Investment in mutual funds (quoted) (non-current)	138.66	-	-	138.66
Investment in mutual funds (quoted) (current)	653.47	-	-	653.47
Investments in other companies (unquoted) (non-current)*	-	-	3.60	3.60
	792.13	-	**3.60**	**795.73**
Financial liabilities (at FVTPL)				
Other financial liabilities (non-current)	-	5.61	-	5.61
Other financial liabilities (current)	-	538.42		538.42
	-	**544.03**	-	**544.03**
Financial assets not measured at fair value				
Other financial assets (non-current)	-	27.07	-	27.07
	-	**27.07**	-	**27.07**
Financial liabilities not measured at fair value				
Borrowings	-	6,002.30	-	6,002.30
	-	**6,002.30**	-	**6,002.30**

Quantitative disclosures fair value measurement hierarchy valued as at March 31, 2025:

(₹ in crores)

March 31, 2025	Level 1	Level 2	Level 3	Total
Financial assets (at FVTPL)				
Investment in mutual funds (quoted) (non-current)	18.65	-	-	18.65
Investment in mutual funds (quoted) (current)	399.07	-	-	399.07
Investments in other companies (unquoted) (non-current)*	-	-	1.18	1.18
	417.72	-	**1.18**	**418.90**
Financial assets not measured at fair value				
Other financial assets (non-current)	-	25.60	-	25.60
	-	**25.60**	-	**25.60**
Financial liabilities not measured at fair value				
Borrowings	-	469.46	-	469.46
	-	**469.46**	-	**469.46**

* The impact of the sensitivity analysis is not material for the company's operations.

Set out below, is a comparison by class of the carrying amounts and fair value of the Company's financial instruments:

As at March 31, 2026

(₹ in crores)

	Note	Carrying value		
		FVTPL	Amortised Cost	Total
Financial assets: *				
Investments in other companies (unquoted) (non-current)	5.1	3.60	-	3.60
Investment in mutual funds (quoted) (non-current)	5.1	138.66	-	138.66
Other Financial assets (non-current)	5.3	-	27.07	27.07
Investment in mutual funds (quoted) (current)	9.1	653.47	-	653.47
Trade receivables	9.2	-	160.74	160.74
Cash and cash equivalents	9.3	-	54.65	54.65
Loans (current)	9.4	-	0.13	0.13
Other financial assets (current)	9.5	-	13.37	13.37
		795.73	**255.96**	**1,051.69**
Financial liabilities:				
Borrowings (includes current maturities of long-term borrowings)	13.1, 15.1	-	6,002.30	6,002.30
Lease liabilities (Non-current and current)	13.2	-	602.37	602.37
Other financial liabilities (non-current)	13.3	5.61	-	5.61
Trade payables	15.2	-	292.51	292.51
Other financial liabilities (current)	16	538.42	26.94	565.36
		544.03	**6,924.12**	**7,468.15**

* excludes investment in subsidiary companies

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

As at March 31, 2025	Note	Carrying value		(₹ in crores)
		FVTPL	Amortised Cost	Total
Financial assets: *				
Investments in other companies (unquoted) (non-current)	5.1	1.18	-	1.18
Investment in mutual funds (quoted) (non-current)	5.1	18.65	-	18.65
Loans (non-current)	5.2	-	12.41	12.41
Other financial assets (non-current)	5.3	-	25.60	25.60
Investment in mutual funds (quoted)	9.1	399.07	-	399.07
Trade receivables	9.2	-	109.47	109.47
Cash and cash equivalents	9.3	-	65.21	65.21
Loans (current)	9.4	-	0.26	0.26
Other Financial assets (current)	9.5	-	12.52	12.52
		418.90	**225.47**	**644.37**
Financial liabilities:				
Borrowings (includes current maturities of long-term borrowings)	13.1, 15.1	-	469.46	469.46
Lease liabilities (Non-current and current)	13.2	-	585.85	585.85
Trade payables	15.2	-	275.00	275.00
Other financial liabilities (current)	16	-	22.56	22.56
		-	**1,352.87**	**1,352.87**

* excludes investment in subsidiary companies

The Company does not have any financial instruments which are measured at FVTOCI

There have been no transfers among Level 1, Level 2 and Level 3 during the year ended March 31, 2026 and year ended March 31, 2025

The Company considers that the carrying amounts of current financial assets and current financial liabilities recognised in the Standalone Financial Statement at amortized cost will reasonably approximate their fair values. The fair value of non-current financial assets and liabilities (Loans, other financial assets, borrowings and lease liabilities) has been measured based on the present value of expected payments, discounted using a risk-adjusted discount rate

(This space has been intentionally left blank)

Manipal Hospitals Private Limited Bengaluru

B S R & Co. LLP

34 Financial risk management

The Company's principal financial liabilities, comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include loans, investments, trade and other receivables and cash and cash equivalents that are derived directly from its operations.

The Company's activities expose it to market risk, credit risk and liquidity risk. The Company's management oversees the management of these risk and works towards minimizing the potential adverse effects, if any, on its financial performance.

A. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises interest rate risk and currency rate risk. Financial instruments affected by market risk include loans and borrowings, payables, investments and bank deposits. The sensitivity analyses in the following sections relate to the position as at March 31, 2026 and March 31, 2025. The sensitivity of the relevant Profit and Loss item is the effect of the assumed changes in the respective market risks. This is based on the financial assets and financial liabilities held as of March 31, 2026 and March 31, 2025.

(i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates in form of Term loans. The Company monitors the movement in interest rates on an ongoing basis.

Exposure to interest rate risk
The interest rate profile of the Company's interest-bearing financial instruments are as follows:

(₹ in crores)

Fixed rate instruments	March 31, 2026	March 31, 2025
Financial asset		
Margin money deposits with banks	12.45	11.70
Deposits with banks due to mature after twelve months from the reporting date	7.77	7.23
Deposits with original maturity of less than three months	-	30.00
Financial liability		
Borrowings (non-current)	5,261.84	-

(₹ in crores)

Variable rate instruments	March 31, 2026	March 31, 2025
Financial asset		
ICD given to related parties	-	12.41
Investments in mutual funds (quoted)	792.13	417.72
Financial liability		
Borrowings (non-current and current)	476.37	469.46

Sensitivity analysis for variable rate instruments
Based on the closing balance of variable instruments, an increase/ decrease in interest rate by 1%, with all other variables remaining constant would result in increase/ decrease in profit or loss and equity by ₹ 3.16 crores (year ended March 31, 2025: ₹ 0.39 crores).

(ii) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a foreign currency). The Company monitors foreign exchange rates on an ongoing basis.

Particulars of unhedged foreign currency exposure as at the reporting date:

Particulars	March 31, 2026			
	USD million	(₹ in crores)	EUR (million)	(₹ in crores)
Import trade payable	0.81	7.30	0.00*	0.00*
Capital creditors	0.79	7.10	-	-

Particulars	March 31, 2025			
	USD million	(₹ in crores)	EUR (million)	(₹ in crores)
Capital creditors	0.03	0.30	0.70	5.70

Foreign currency risk sensitivity
The sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments. The following table demonstrates the sensitivity to a reasonably possible change in USD exchange rates, with all other variables held constant:

Depreciation of INR against USD and EURO by 1% results in decrease in profit before tax by ₹ 0.14 crores (March 31, 2025: 0.01 crores) and appreciation of INR against USD and EURO by 1% results in increase by such amount.

* Represents value less than ₹ 0.01 crore or EUR 0.01 million

B. Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its trade receivables, cash and cash equivalents and financial assets.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the management.

(i) Trade and other receivables:
The Company's exposure to credit risk is influenced mainly by the characteristics of each customer. Credit risk is controlled by analyzing credit limits and creditworthiness of payors/customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.

Loss rates are based on actual credit loss experience over the past few years, current conditions and forecasts of future economic conditions.

Refer note 9.2.2 for information about the exposure to credit risk and ECLs for trade receivables.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

The movement in the allowance for impairment in respect of trade receivables during the year is as follows:

(₹ in crores)

	March 31, 2026	March 31, 2025
Opening balance	19.28	14.52
Loss allowance on trade receivables (net of reversals)	9.02	4.76
Closing balance	**28.30**	**19.28**

There is no significant concentration of credit risk and no single customer accounted for more than 10% of the revenue as of March 31, 2026 and March 31,2025.

(ii) Other receivables:

The Company establishes an allowance for impairment that represents its estimate of expected losses in respect of other receivables based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from other receivables amounting to ₹ 0.72 crores (March 31, 2025:₹ 0.60 crores). The movement in allowance for impairment in respect of other receivables during the year was as follows:

(₹ in crores)

	March 31, 2026	March 31, 2025
Opening balance	0.28	0.18
Loss allowance on other receivables (net)	0.10	0.10
Closing balance	**0.38**	**0.28**

(iii) Financial instruments and deposits:

Credit risk on cash and cash equivalents is limited as the Company generally transacts with banks with high credit ratings assigned by international and domestic credit rating agencies. Investments of surplus funds, temporarily, are made only with approved counterparties who meet the minimum threshold requirements under the counterparty risk assessment process.

C. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Also, the Company has unutilized credit limits with banks. (Refer Note 2.1 (b))

The table below summarises the maturity profile of the Company's financial liabilities based on undiscounted contractual payments:

(₹ in crores)

	March 31, 2026		
	Less than 1 year	More than 1 year	Total
Borrowings (includes current maturities of long-term borrowings)	844.98	6,327.16	7,172.14
Lease liabilities (non-current and current)	76.95	1,958.02	2,034.97
Trade payables	292.51	-	292.51
Other financial liabilities (non-current and current)	565.36	5.61	570.97

	March 31, 2025		
	Less than 1 year	More than 1 year	Total
Borrowings (includes current maturities of long-term borrowings)	98.18	590.20	688.38
Lease liabilities (non-current and current)	72.57	2,009.62	2,082.19
Trade payables	275.00	-	275.00
Other financial liabilities (non-current and current)	22.56	-	22.56

35A Capital management

The primary objective of Company's capital management is to ensure that it maintains an optimum financing structure and healthy returns in order to support its business and maximize shareholder value.

The Company manages its capital structure and makes adjustments, in light of the changes in economic conditions or business requirements.

The Company monitors capital using a gearing ratio which is net debt divided by total equity plus net debt as shown below.
- Net debt includes borrowings, lease liabilities (non-current and current) less cash and cash equivalents and investments in mutual funds and
- Total equity comprises of issued share capital and all other equity components attributable to equity share holder.

(₹ in crores)

	March 31, 2026	March 31, 2025
Borrowings (note 13.1)	6,002.30	469.46
Lease liabilities (note 13.2)	602.37	585.85
Less: Cash and cash equivalents (note 9.3)	(54.65)	(65.21)
Less: Investment in mutual funds (quoted) (refer note 5.1 & 9.1)	(792.13)	(417.72)
Net debt (A) (including lease liabilities) #	**5,757.89**	**572.38**
Total equity attributable to the equity shareholders of the Company (note 11 and note 12)	1,457.16	1,250.63
Total capital (B)	**1,457.16**	**1,250.63**
Capital and net debt (C = A+B)	**7,215.05**	**1,823.01**
Gearing ratio (D = A / C)	**80%**	**31%**

Investments in mutual funds are adjusted as the Company may use these investments for strategic purposes including payment of debt

35B During the year ended March 31, 2023, the Income Tax department conducted a search under section 132 of the Income Tax Act, 1961 at the registered office of the Company and one hospital location. During the course of the search proceedings, certain information and documents were sought by the department. On March 29, 2024, Company has received the assessment order comprising demand u/s 156 of the Income Tax Act, 1961 for the Assessment Year (AY) 2019-20 amounting to Rs. 1.68 crore (including interest) & for AY 2022-23 amounting to Rs. NIL towards disallowance of certain expenses. On March 3, 2025, the Company has received assessment order with respect of above mentioned matter, comprising demand u/s 156 of the Income Tax Act, 1961 for AY 2020-21 amounting to Rs. 0.39 crore(including interest), for AY 2021-22 amounting to Rs. NIL and for AY 2023-24 amounting to Rs. 0.67 crore (including interest) towards disallowance of certain expenses.

In October, 2025, the Company has received assessment order comprising demand u/s 156 of the Income Tax Act, 1961 for AY 2024-25 amounting to Rs.0.84 crore (including interest). The Company has filed appeal with CIT (A).

In May, 2026 the Company had received favourable CIT(A) order u/s 250 for AY 2019-20, AY 2020-21, AY 2021-22, AY 2022-23, AY 2023-24 and AY 2024-25.

B S R & Co. LLP

Manipal Hospitals Private Limited Bengaluru

36 Segment information:

The Board of Directors of the Company has been identified as the Chief Operating Decision Maker (CODM) as defined by Ind AS 108, Operating Segments. The Company operates in a single business and geographical segment (Healthcare services in India) and the CODM reviews the financial information at an entity level. Hence, the Company has determined that disclosures given at the entity level suffices the disclosure requirements of Ind AS 108.

Refer note 1.

37 Corporate Social Responsibility ('CSR') expenditure

Consequent to the requirements of Section 135 and Schedule VII of the Companies Act, 2013, the Company is required to contribute 2% of its average net profits during the immediately three preceding financial years in pursuance of its Corporate Social Responsibility Policy.

(a) Gross amount approved by the Board and required to be spent by the Company for the year ended March 31, 2026 is ₹ 6.37 crores (March 31, 2025: ₹ 4.59 crores).

(b) Amount spent:
Promoting healthcare, education, gender equality, ensuring environment sustainability, training for rural sports and rural development objects.

(₹ in crores)

	In cash	Yet to be paid in cash	Total
Year ended March 31, 2026	6.37	-	6.37
Year ended March 31, 2025	4.59	-	4.59

(c) Details related to spent / unspent obligations:

(₹ in crores)

	March 31, 2026	March 31, 2025
(i) Contribution to Public Trust	-	-
(ii) Contribution to Charitable Trust	6.37	4.59
(iii) Unspent amount in relation to:		
- Ongoing project	-	-
- Other than ongoing project	-	-
	6.37	**4.59**

Details of other than ongoing project

As on March 31, 2026

Opening balance	Amount deposited in Specified Fund of Sch. vii within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance
-	-	6.37	6.37	-

As on March 31, 2025

Opening balance	Amount deposited in Specified Fund of Sch. vii within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance
-	-	4.59	4.59	-

38 Reconciliation of movements of liabilities to cash flows arising from financial liabilities

(₹ in crores)

	Term loans	Non-Convertible debentures	Lease liability	Loan for purchase of capital asset	Total
Debt as at April 01, 2025	467.47	-	585.85	1.99	1,055.31
Interest accrued but not due as at April 01, 2025	0.06	-	-	-	0.06
Addition during the year	-	-	21.56	-	21.56
Cash flows including interest paid					
- Proceeds from borrowings	68.05	5,310.00	-	0.40	5,378.45
- Repayment of borrowings / lease obligations	(61.07)	-	(10.99)	(0.80)	(72.86)
- Interest paid	(35.03)	(23.30)	(65.90)	(0.13)	(124.36)
Non-cash changes					
- Ind AS adjustment with respect to unamortised loan processing charges	0.33	(24.86)	-	-	(24.53)
- Lease termination/adjustments	-	-	(2.15)	-	(2.15)
- Interest expense	35.01	264.05	74.00	0.13	373.19
Debt as at March 31, 2026	**474.82**	**5,525.89**	**602.37**	**1.59**	**6,604.67**

	Term loans	Lease liability	Loan for purchase of capital asset	Total
Debt as at April 01, 2024	427.24	569.51	1.86	998.61
Interest accrued but not due as at March 31, 2024	0.09	-	-	0.09
Addition during the year	94.24	18.70	0.45	113.39
Cash flows including interest paid				
- Repayment of borrowings	(54.46)	(11.72)	(0.32)	(66.50)
- Interest paid	(35.79)	(60.29)	(0.16)	(96.24)
Non-cash changes				
- Lease termination/adjustments	-	(0.46)	-	(0.46)
- Interest expense	36.21	70.11	0.16	106.48
- Interest capitalised	-	-	-	-
Interest accrued but not due as at March 31, 2025	(0.06)	-	-	(0.06)
Debt as at March 31, 2025	**467.47**	**585.85**	**1.99**	**1,055.31**

39 Below are the details of subsidiary along with proportion of ownership interest held and country of incorporation

Investment in subsidiary:

Name of the Company	Country of Incorporation	Percentage of ownership interest held (directly and indirectly) and voting rights held as at	
		March 31, 2026	March 31, 2025
Manipal Hospitals (East) India Private Limited (MHEIPL) (formerly known as AMRI Hospitals Private Limited)	India	84.07%	84.07%
Sahyadri Hospitals Private Limited (SHPL)	India	89.98%	-

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

40 Accounting ratios

i) Current ratio
The current ratio is used to assess a company's short term liquidity. It is calculated by dividing the current assets by current liabilities.

ii) Debt-equity ratio
"Total debt" is defined as aggregate of non-current borrowings and current maturities of long term-borrowings and total equity includes issued capital and all other equity reserves

iii) Debt service coverage ratio
The Debt Service Coverage Ratio (DSCR) measures the ability of a company to use its operating income to repay all its debt obligations, including repayment of principal and interest on both short-term and long-term debt. It is calculated by dividing net operating income by the total debt service (Interest and principal)

iv) Return on equity ratio
Equal to profit for the year divided by the equity during that period, and is expressed as a percentage.

v) Inventory turnover ratio
Inventory turnover indicates the rate at which a company sells and replaces its stock of goods during a particular period. The inventory turnover ratio formula is the cost of goods sold divided by the average inventory for the same period

vi) Trade receivables turnover ratio
Accounts receivable turnover ratio is calculated by dividing your revenue from operations by your average accounts receivable. The ratio is used to measure how effective a company is at extending credits and collecting debts.

vii) Trade payables turnover ratio
This ratio is used to measure the number of times the business is paying off its creditors or suppliers in an accounting period. It is computed by dividing the total purchases by average accounts payable.

viii) Net capital turnover ratio
It is calculated by dividing annual sales by average stockholder equity (net worth). The ratio indicates how much a company could grow its current capital investment level.

ix) Net profit ratio
The net profit percentage is the ratio of after-tax profits to net sales. It reveals the remaining profit after all costs of production, administration, and financing have been deducted from sales, and income taxes

x) Return on capital employed
Return on Capital Employed is calculated by dividing our EBIT during a given period by Capital Employed (net worth, total debt, deferred tax liability) during that period.

xi) Return on investment
Return on investment (ROI) is a performance measure used to evaluate the efficiency or profitability of an investment or compare the efficiency of a number of different investments. To calculate ROI, the benefit (or return) of an investment is divided by the cost of the investment.

Ratio	Numerator	Denominator	As at March 31, 2026	As at March 31, 2025	% change	Reason for variance
i) Current ratio	Current assets	Current liabilities	0.75	1.55	-51%	The variance is due to increase in accrued interest and current liabilities
ii) Debt-equity ratio	Total Debt	Total Equity	4.12	0.38	997%	The variance is due to increase in borrowings during the year.
iii) Debt service coverage ratio	Earnings available for debt service= Net Profit after tax+ Non cash operating expenses+ Interest + Other adjustments like loss on sale of fixed assets, etc	Debt service= Interest & lease payments + Principal Repayments	1.44	3.24	-56%	The variance is due to decrease in profit for the year
iv) Return on equity ratio %	Net Profit after tax	Average Shareholders equity	15.21%	30.51%	50%	The variance is due to decrease in profit for the year
v) Inventory turnover ratio	Cost of Goods sold = opening inventory + purchases - closing inventory	Average Inventory	12.56	12.39	1%	NA
vi) Trade receivables turnover ratio	Revenue from operations	Average Accounts Receivable	18.31	22.23	-18%	NA
vii) Trade payables turnover ratio	Total Purchases	Average Trade Payables	1.50	1.15	31%	The variance is due to increase in purchases during the year.
viii) Net capital turnover ratio	Net sales	Average Shareholders equity	1.83	1.98	-8%	NA
ix) Net profit ratio %	Net Profit	Net Sales	8.32%	15.38%	46%	The variance is due to decrease in profit for the year
x) Return on capital employed %	Earnings before interest and taxes	Capital Employed = Net Worth + Total Debt + Deferred Tax Liability	9.58%	32.26%	-70%	The variance is due to increase in borrowings during the year.
xi) Return on investment %	Interest (Finance Income)	Investment in fixed deposits as at year end	105.89%	2.98%	3449%	The variance is due to increase in investment in Bank deposits during the year

B S R & Co. LLP

Manipal Hospitals Private Limited
Bengaluru

41 Dues to Micro and Small Enterprises as per the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED):

(₹ in crores)

	March 31, 2026	March 31, 2025
(i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	8.86	6.11
(ii) Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	-
(iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(iv) Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(v) Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
(vi) Interest due and payable towards suppliers registered under MSMED Act, for payments already made	-	-
(vii) Further interest remaining due and payable for earlier years	-	-

42 Other Statutory Information

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(ii) The Company does not have any transactions with companies struck off under section 248 of Companies Act, 2013 or section 560 of Companies Act, 1956.

(iii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period,

(iv) The Company is in compliance with number of layers of companies, as prescribed under clause (87) of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017,

(v) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

(vi) During the year ended March 31, 2026, has no funds have been advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

The Company has complied with relevant provisions of the applicable law for this transaction. The Company has complied with relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999), to the extent applicable, the Companies Act, 2013 for such transaction and this transaction is not violative of the Prevention of Money-Laundering Act, 2002 (15 of 2003).

(vii) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,

(viii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

(ix) The Company has not been declared wilful defaulter by any bank or financial institution or other lender.

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm Registration number : 101248W/W - 100022

G Prakash
Partner
Membership number: 099696

Place : Bengaluru
Date : May 22, 2026

For and on behalf of the Board of Directors of
Manipal Hospitals Private Limited

Dr. H. Sudarshan Ballal
Chairman

Deepak Venugopalan
Chief Executive Officer

Pratik Gupta
Chief Financial Officer

Khadija G Vahora
Company Secretary
Membership number: A37266

Place : Bengaluru
Date : May 22, 2026